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ABSTRACT
SYNTHETIC APPROACHES TO THE UNDERSTANDING OF DNA
NUCLEOBASE METHYLATION
By
Jagruti Rana

DNA methylation is a major source of genetic variation and cancer. Methylation occurs
when nucleophilic DNA bases react with methylating agent methyl methanesulfonate
(MMS), dimethyl sulfate (DMS), N-methyl-N-nitrosourea (MNU), N-methyl-N′-nitro-Nnitrosoguanidine (MNNG), etc. N7-methyl-2ʹ-deoxyguanosine (N7-methyl-dG, or 7MedG)
adduct is the most abundant DNA methylation products for most methylating agents.
DNA polymerase actions on 7MedG are difficult to study due to its instability against ringopening hydrolysis and deglycosylation. Oligonucleotides containing a single chemical
adduct of 7MedG cannot be chemically synthesized. In addition,

7Me

dG is unstable in vivo

due to the presence of DNA repair enzymes. This work explores the possibility of using
stable analogues of N7-methyl-dG to study the polymerase bypass. The chemical
synthesis of N7-methyl-9-deaza-dG (7Me9CdG) has been developed and the nucleoside has
been successfully incorporated into oligonucleotides. Thermal melting studies show that
replacement of dG by 7Me9CdG only slightly decreases DNA duplex stability. Replication
of the DNA templates containing 7Me9CdG and the related 7-methyl-7-deaza-dG (7Me7CdG)
and 7-deaza-dG (7CdG) by Klenow fragment of E. coli DNA polymerase I is examined.
The misincorporation frequencies on the

7Me9C

dG,

7Me7C

dG, and

7C

dG templates are

comparable to the dG template, although the 7-methyl group slows down the turnover
rate of the polymerase when dCTP is incorporated. The stability of

7Me9C

dG and

7Me7C

dG

against the actions of formamidopyrimidine DNA N-glycosylase (Fpg) and human

alkyladenine DNA Glycosylase (hAAG) are also studied.

7Me9C

dG is stable in the

presence of both enzymes. In contrast, 7Me7CdG is cleaved by Fpg, and possibly by hAAG
but in an extremely slow rate. This work demonstrates that

7Me9C

dG is a better analogue

than 7Me7CdG for future cellular studies.
Epigenetic mechanisms regulate the expression of genetic information. A major
epigenetic event is DNA cytosine methylation, which is catalyzed by the DNA
methyltransferases (DNMTs). Among different mammalian DNMTs, DNMT1 is the
most abundant and active, and plays multiple roles in carcinogenesis, embryonic
development, and several other biological functions. Reactivation of silenced tumor
suppressor genes by DNMT inhibitors (DNMTi) is provides a relatively new approach to
cancer therapy. A couple of irreversible nucleoside DNMT inhibitors have been
developed clinically. However, due to their low specificity and high cellular toxicity,
there is a clear need for the development of reversible inhibitors. S-adenosyl
homocysteine (SAH) is a known strong inhibitor of DNA methyltransferases. Based on
the crystal structure of SAH bound to human DNMT1-DNA complex, a series of
transition state analogues have been designed to occupy the SAH binding site and the
cytosine binding site simultaneously. These analogues have been successfully
synthesized from adenosine using a modular approach. Inhibition of DNMT1 by these
analogues will be studied in the future.
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CHAPTER 1
GENERAL INTRODUCTION

1.1 DNA Damage and Mutation
Deoxyribonucleic acid (DNA) is a molecule that encodes the genetic instructions used in
each living cell; its integrity and stability are essential to life. The sequence of bases in
the interior of DNA double helix constitutes the genetic code that is critically important
for all organisms. Each strand is comprised of a sugar-phosphate backbone and attached
bases, and is bound to a complementary strand by non-covalent hydrogen bonding and
stacking interactions. The bases are adenine (A), thymine (T), cytosine (C) and guanine
(G), where A and T are paired together by two hydrogen bonds and G and C are paired
together by three hydrogen bonds (Figure 1.1). The chemical view of DNA acknowledges
the unique shape of each base and position of the functional groups that distinguish the
four ‘letters’ of the alphabet. The twisting of the double helix results in the DNA having
two distinct grooves, the major and minor grooves. The major groove is shallow and wide
and this is where many proteins and enzymes interact with DNA. The minor groove is the
deep and narrower groove. Chemical modifications on DNA can change the shape,
electrostatics, or conformer distribution of the duplex. These changes enable enzymes to
specifically recognize chemical modifications. This type of specific molecular
recognition has a profound implication for DNA damage repair, gene mutation, and
epigenetic control.

1

2

Figure 1.1 DNA base pairing (G with C and A with T), and the major and minor grooves.

Cellular DNA is constantly subjected to modifications by aging processes,
environmental influences, and lifestyle factors such as smoking- or diet-induced
biochemical alterations to DNA. Frequently, these lead to DNA lesions. Although DNA
lesions play an essential role in the formation of cancer via carcinogens, it is also one of
the major mechanisms used for the treatment of cancer via chemotherapeutic agents and
radiation therapy. When chemotherapeutic agents are used for the treatment of cancer, the
biological end points can lead to either a positive clinical outcome (killing the cancer
cells) or a negative outcome (mutations leading to secondary cancers from the initial
treatment). This mixed cytotoxic and genotoxic effects were observed in the early
development of chemotherapeutic agents such as Dacarbazine and Procarbazine.1 The
determining factor on whether the damage will lead to cell death or mutations is the
processing of the damage by the cell. DNA damages and mutations differ in fundamental
ways. Damages are physical irregularities in the DNA, such as the formation of DNA
adducts and single- and double-strand breaks. They also include the formation of
mismatched nucleobases arising from erroneous replication of undamaged nucleosides.
Because damage can be recognized enzymatically, they can be correctly repaired if
redundant information is available. If damage remains in a gene, it can prevent
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transcription of the gene, and thus production of a protein or it can be incorrectly
replicated or transcribed, causing mutations. On the other hand, a mutation is a change in
the base sequence of the genetic material and is not enzymatically recognizable at the
DNA level once the base change is present in both strands. Mutations can be caused by
poor replication of damaged DNA or undamaged DNA, although the error rate on
damaged DNA is much higher. Mutations in a cell can cause alterations in protein
function or regulation. They are replicated when the cell replicates. In a population of
cells, mutant cells will increase or decrease in frequency according to the effects of the
mutation on the ability of the cell to survive and reproduce.
Therefore, although distinctly different from each other, DNA damages and
mutations are closely related. Numerous DNA lesions have been identified, including
covalent modifications of nucleobases with chemicals, depurination from the backbone of
DNA, oxidative damage on deoxyribose, and subsequent generation of DNA strand
interruption resulting from depurination and sugar oxidative damage.2 Naturally
occurring DNA damages arise more than 60,000 times per day per mammalian cell. 2
Fortunately, our cells have evolved powerful mechanisms to detect and repair the various
types of damage that can occur to DNA. Whether this damage is caused by chemical
reactions or by errors in replication of undamaged nucleosides, it is repaired by one of the
three excision repair pathways: nucleotide excision repair (NER), base excision repair
(BER), and DNA mismatch repair (MMR). BER is responsible primarily for removing
small, non-helix-distorting base lesions from the genome, for example, alkylation damage
such as the formation of N7-methylguanine (N7-Me-G), N3-methyladenine (N3-Me-A)
and O6-Methylguanine (O6-Me-G), oxidative damage such as 8-oxoguanine (OG)(Figure

4
1.2).2 The related nucleotide excision repair pathway repairs bulky helix-distorting
lesions. If remaining unrepaired, damaged bases could otherwise cause mutations by
mispairing during replication or lead to strand breaks in DNA. DNA mismatch repair is a
system for recognizing and repairing erroneous insertion, deletion, and mis-incorporation
of bases that arise during DNA replication and recombination.

Figure 1.2 Structures of DNA base lesions.

During the cell cycle, checkpoint mechanisms ensure that cellular DNA is intact
before permitting DNA replication and cell division to occur. Failures in these
checkpoints can lead to an accumulation of damage, which in turn leads to mutations or
epigenetic alterations.3 Both of these types of alteration can be replicated and passed on
to subsequent cell generations. These alterations can change gene function or regulation
of gene expression and possibly contribute to progression to diseases such as cancer.
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Among them, the biological effects of DNA methylation have long been an interest of
researchers, especially those on the formation of cancers.

1.2 DNA Methylation
Humans are exposed to methylating agents in daily life.4 The attack on DNA by these
electrophilic methylating agents can lead to various types of lesions on the heterocyclic
bases or backbone (Figure 1.3). Most of these resulting adducts are mutagenic or
cytotoxic. The nucleophilicities of different reaction sites in DNA have been well studied.
The exocyclic amino groups of guanine, cytosine, and adenine are poor nucleophiles in
methylation reactions. Although each ring nitrogen and exocyclic oxygen is potentially
capable of acting as a nucleophile, their reactivity towards electrophiles substantially
varies by position and whether the DNA is single- or double-stranded. The most reactive
sites of nonenzymatic DNA methylation (see next paragraph) are the ring nitrogen’s of
purine bases. Among them, the N7 position of guanine is the most nucleophilic site.5
Molecular electrostatic potentials of the nucleophilic sites on the bases and base pairs
showed that the N7 position of guanine possesses the highest negative electrostatic
potential in DNA.6 In double-stranded DNA, O6-guanine and N3-adenine have the next
highest potential, followed by N3-guanine, O2-cytosine, N7-adenine, O4-thymine and
O2-thymine.6 The negative electrostatic potential is larger on the major groove for a
guanine:cytosine base pair, whereas it is larger on the minor groove for an adenine:
thymine base pair.
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Figure 1.3 Methylation patterns of the DNA bases. (The arrows indicate methylation
sites.4 )

In single-stranded DNA, it is worth noting that N3-cytosine has a similar negative
electrostatic potential to that of N7-guanine, while N1-adenine has a similar potential to
that of O6-guanine.6 N1-adenine and N3-cytosine have a reactivity characteristic of
amidine groups due to the adjacent amino groups on the neighboring carbons. These two
positions are protected by hydrogen bonding in double-stranded DNA (dsDNA) but are
quite nucleophilic in single stranded DNA (ssDNA) due to the absence of hydrogen
bonding participation. The pKa’s of these two nitrogen sites are 4.1 and 4.5 in ssDNA,
which are higher than that of N7-guanine.7
Consideration of electrostatic potentials and steric hindrances help in part explains
the reaction preferences seen with methylating agents, but the type of agents also
influences the distribution of adducts. Methyl methanesulfonate (MMS), dimethyl sulfate
(DMS), N-methyl-N-nitrosourea (MNU), and N-methyl-N′-nitro-N-nitrosoguanidine
(MNNG) have been used extensively to study the chemical and biological effects of
methylation. Understanding of the distribution is important for the evaluation of
methylating outcome, as different lesions also have different mutagenic and cytotoxic
effects. For example, it was observed that N7-methyl-dG (7MedG) was the major adduct
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when DNA was exposed to all the above methylating agents.8 However, the reactions
occur through two different pathways: the SN1 (unimolecular nucleophilic substitution)
and the SN2 (biomolecular nucleophilic substitution) pathways. (Figure 1.3); The SN1
type methylating agents such as MNU and MNNG, also attack on the oxygen atoms on
DNA bases to give a significant amount of O6-methylguanine (O6-Me-G) and a small
amount of O4-methylthymine (O4-Me-T).9 The SN2 type methylating agents such as
MMS and DMS generate overwhelmingly N7-Me-G.9 Experimental data show that
treating dsDNA with MMS (SN2 type methylating agent) produced 83 % of N7-Me-G
whereas MNU ( SN1 type methylating agent) produced 67 % of N7-Me-G.4 The more
significant difference in reactivity between MMS and MNU lies in the proportion of
oxygen adducts. In addition to N7-Me-G, MMS produced 11% N3-methyladenine (N3Me-A) and 0.3% O6-Me-G, whereas MNU produced 12% N3-Me-A and 7% O6-MeG.10 The remaining base positions N1-adenine, N7-adenine, N1-guanine, N3-guanine,
N3-cytosine, O2-cytosine, N3-thymine, O2-thymine, and O4-thymine combined
comprise <5% of the adduct burden in dsDNA produced by MMS or MNU.10
The events of human DNA methylation in daily lives originate from a wide
variety of sources, including foods, beverages, tobacco, cosmetics, and industrial
products.11 Detailed understanding of the biochemical fate of methylation adducts
becomes extremely important. Although the N7-position is the major site of methylation,
compared to many other DNA adducts, N7-guanine adducts are chemically unstable with
half lives in dsDNA ranging from as little as 2 h to 150 h.12 The instability of N7-guanine
adducts is created by the formal placement of an additional positive charge on the
guanine ring system.4 Although this instability can eventually result in DNA strand break,
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which leads to cytotoxicity, numerous studies have suggested that N-methyl-G itself is
not very mutagenic. In contrast, O-alkylations (e.g., O6-alkylguanine and O4alkylthymidine) are highly mutagenic based on a variety of solid evidence.13
Nevertheless, we chose to study N7-methyl-dG (7MedG) since direct observation of the
nonmutagencity of N7-methyl-dG is lacking at the molecular level in vitro due to its
instability. N7-guanine adducts have been classified as nonmutagenic based on the
speculation that the N7-position does not participate in Watson-Crick base pairing.14
However, this information can only be verified experimentally by the study of how DNA
polymerases process the damage which is an essential step in the eventual biological
endpoint of the damage. Because of its inherent instability

7Me

dG has been unable to be

chemically synthesized and incorporated into oligonucleotide substrates suitable for DNA
polymerase assays. Using the stable analogues of 7MedG, we have developed a strategy to
generate models of

7Me

dG-containing substrates, which are suitable for the study of their

interactions with DNA polymerases. This is the focus of my first project.

1.3 DNA Methylation and Epigenetics
In contrast to exogeneous agents, methylating agents also exist endogenously inside
cells; for instance, S-adenosylmethionine(SAM), a methyl donor for many cellular
reactions, has been shown to produce methylation products such as epigenetic DNA
modification 5-methylcytosine (MeC). There are over 200 different types of cells in the
human body. Each type maintains a unique cellular identity represented by the specific
sets of genes they transcribe. Because the genetic material in each of these cells is
essentially identical, there must be strict regulation of gene expression in each cell within
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the human body. This transcriptional regulation is carried out by controlling the
accessibility to genes. This layer of control is achieved by the packaging of DNA into
particular arrangements. DNA is wrapped around proteins called histones, which are
structurally organized and condensed into chromatin. Histone proteins can be modified,
and these modifications serve as important regulators in the transcription of necessary
genes throughout the life cycle of an organism. In mammals, the methylation on specific
sites of DNA called CpG islands is an additional method of transcriptional control. In
nucleic acid chemistry, adjacent nucleotide pairings are sometimes referred to in an NpN
fashion, where N is the base and p is the phosphodiester bond; thus, CpG is the
designation given to cytosine phospho guanine. The frequency of the CpG dinucleotide is
very low (or rather, sporadic) in the human genome. It has been estimated that genomic
DNA consists of about 10% CpG dinucleotides, which are unevenly distributed between
bulk DNA and CpG islands.15 Histone modifications and CpG island methylation are
collectively called epigenetic; a term defined as heritable changes in gene expression that
occur without a change in the DNA sequence.
Previously, scientists have attributed a person phenotype’s characteristics based
solely on the composition of the persons genomic DNA. It is through the genetic
composition and alterations that we have studied the neoplastic evolution and were
confounded to the idea that cancer was mainly a disease of genetics. Recently, the study
of external influences on the DNA has come to question this idea in favor of a much
larger complex mechanism which involves the abnormal epigenetic control. Epigenetic
control at the chromatin level is essential for all eukaryotic organisms, and is especially
important in multicellular organisms to organize key biological processes such as
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differentiation, imprinting, X-chromosome inactivation and aging. Cellular differentiation
is the best example of epigenetic changes. All multi-cellular organisms, including
animals originate from a single cell after fertilization of an egg by a sperm. Therefore all
cells in a given organism will have the same genome, but during fetal development each
cell will gain a specific set of epigenetic marks. DNA methylation is such an epigenetic
mark that stably regulates cell differentiation. While uncontrolled cell differentiation is a
character of cancer cells, understanding of the relationship between DNA methylation
regulation and cancer formation becomes critical in elucidating this complex mechanism.
Uncontrolled differentiation is often a result of silenced cancer-suppressor genes.
CpG islands are normally not methylated, however, if a CpG island within a promoter
becomes methylated, the gene associated with the promoter is permanently silenced, and
this silencing can be transmitted through mitosis. This means that CpG island
methylation is an epigenetic means of inheritance. So far, the generally accepted
mechanism of DNA methylation in regulating gene expression and gene silencing can be
classified into two mechanisms. The first is that CpG methylation alters the secondary
conformation of DNA from the B form to the Z form, a much more compact form with a
deeper groove. This disrupts the interactions between specific transcription factors and
gene promoters, consequently resulting in the direct inhibition of gene transcription.16
The second mechanism is that CpG methylation leads gene regulation regions near the 5′
end to complex with methyl CpG-binding protein (MBD).17 Under the network of
mCpG-MBD complexes, histones become more positively charged and bind more tightly
with DNA, making chromatin more compact. Thus, the binding of transcription factors
with DNA is limited and transcription is inhibited.
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1.4 DNA Methylation and Cancer
Early studies using global measurement of 5-methylcytosine content in normal and
neoplastic tissues suggested that decreased DNA methylation levels is a common feature
of cancer.18 However, a more recent study by Costello et al. (2000) suggested that
relationship between the global methylation levels and cancer formation is dependent on
the type of cancer cells., Certain tumor types, like breast, head and neck, and testicular,
displayed a relatively low frequency of aberrant methylation while other tumors such as
colon, glioma, and acute myeloid leukemia, displayed a significantly higher frequency of
aberrant methylation events. It was estimated that an average of 608 (up to as many as
4500) CpG islands were aberrantly hypermethylated in tumors.19 Methylation
abnormalities were detectable in both low and high-grade malignancies, supporting the
notion that methylation changes can be an early event in tumor progression. Furthermore,
CpG island methylation was not random indicating that certain CpG islands may be more
susceptible to de novo methylation than others or that selective loss of expression from
certain CpG island associated genes may be favored if loss of that gene provides the cell
with a growth advantage.
The reaction of CpG island methylation features the addition of a methyl group at
the carbon-5 (C5) position of cytosine residues. The level of CpG island methylation is
controlled by DNA methyltransferase (DNMT), an enzyme that catalyzes the transfer of a
methyl moiety from SAM to the C5 position. All DNMTS are essential for normal
development, as it was shown that mice lacking any of the DNMTs died at fetal
development stage or early after birth.20 The mammalian DNMTs family encompasses
DNMT1, DNMT3A and DNMT3B.
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Figure 1.4 Methylation pattern in genomic DNA.21, 22

The maintenance DNMT1 is the most abundant methyltransferase in mammalian
cells. It transfers methyl groups to the hemimethylated DNA during replication, whereas
the de novo DNMT3A and DNMT3B add methyl groups to CpG dinucleotides of
unmethylated DNA (Figure.1.3). Hemimethylated DNA is referred to as a duplex DNA
where only one of two (complementary) strands is methylated (Figure.1.4). A
hemimethylated site is a single CpG that is methylated on one strand, but not on the
other. Hemimethylation is important because it directly identifies de novo methylation
events, allowing differentiation between de novo vs. maintenance factors. The structure
of mammalian DNMTs can be divided into two major parts, a large N-terminal regulatory
domain of variable size, which has regulatory functions, and a C-terminal catalytic
domain which is conserved in eukaryotic and prokaryotic carbon-5 DNMTs (Figure 1.5).
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Figure 1.5 Members of mammalian DNMTs family. The N-terminus of DNMT1
includes a proliferating cell nuclear antigen binding domain (PDB), nuclear localization
signal sequence (NLS), a cysteine rich zinc finger DNA binding motif (ATRX),
polybromo homology domain (PHD); while Dnmt3a and Dnmt3b consist of a
tryptophan-rich region (PWWP), ATRX and PHD.23, 24

The N-terminal regulatory and the C-terminal catalytic domains are linked by a
short fragment of repeated GK dipeptides. The N-terminal domain possesses nuclear
localization signal sequence (NLS) responsible for localization of DNMTs in the nucleus.
The N-fragment of DNMTs also contains proliferating cell nuclear antigen binding
domain (PDB), a cysteine rich zinc finger DNA binding motif (ATRX), and polybromo
homology domain (PHD) targeting DNMTs to the replication foci. However, PWWP, a
tetrapeptide that interacts with histones, is only present in N-terminal domains of
DNMT3A and DNMT3B.25 The C-terminal domain contains six conservative motifs I,
IV, VI, VIII, IX and X. Motifs I and X form SAM binding site, motif IV binds cytosine at
the active site, motif VI possesses glutamyl residue donating protons, and motif IX
maintains the structure of the target recognition domain (TRD) usually located between
motifs VIII and IX, that makes base-specific contacts in the major groove of DNA.26 In
contrast to DNMT1, C-terminal domain of DNMT3A and DNMT3B is active without
interaction with their N-regulatory regions. These differences between DNMT1 and de
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novo DNMTs may provide the structural basis for the design of selective DNMT1
inhibitors.
Since many tumors suppressor genes are silenced by DNA methylation during
carcinogenesis, Reexpression of methylation silenced tumor suppressor genes by
inhibiting the DNMT can lead to suppression of tumor growth or provide novel
opportunities for anticancer therapy. Inhibition of the activity of these proteins will
therefore result in progressive reduction of DNA methylation in newly dividing cells. My
second project is focused on the development of DNA methyltransferase inhibitors.

CHAPTER 2
CHEMICALLY STABLE ANALOGUES OF 7-METHYL-2ʹDEOXYGUANOSINE

2.1 Introduction
N7-methylated guanine adducts are the most abundant products when DNA is exposed to
many methylating agents found in industrial products, food substances, and tobacco
smoke. Methylating agents constitute one of the best studied groups of model genotoxic
chemicals, represented by such laboratory classics as, N-methyl-N-nitrosourea (MNU),
methyl-N′-nitro-N-nitrosoguanidine (MNNG) and methyl methanesulfonate (MMS). In
addition to their wide use in experimental genetic toxicology, methylating agents are of
interest in view of the known human exposure to them and the possible genetic risks
associated with it. Relatively small population subgroups suffer limited workplace
exposure to weakly genotoxic methylating chemicals such as dimethyl sulfate (DMS) and
methylbromide.27 On the other hand, of potentially greater public health significance is
the exposure of the general population to strongly carcinogenic methylating agents such
as N-nitrosodimethylamine (NDMA) and 4-methylnitrosamino-1-3-pyridyl-1-butanone
(NNK). These nitrosamines are present in significant quantities in tobacco smoke, while,
in addition, NDMA is also found in nitrate- or nitrite-treated foods, certain beverages,
and certain occupational settings.11,

28

Although neither NDMA nor NNK is reactive

toward DNA, they can be converted by liver cytochrome P450 enzymes to the highly
reactive N-nitrosomethylamine (Figure 2.1).
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Figure 2.1 Formation of N7-Methyl-dG (7MedG) adduct from NNK.

DNA methylation can occur "naturally" as well. There are also endogenous
methylating agents such as SAM, which is required for the enzymatic conversion of
cytosine into 5-MeC as part of the DNA methylation pathway that helps regulate gene
expression. Alternatively, SAM can act as a weak DNA methylating agent through
nonenzymetic reactions.29 Human can also be exposed to methylating agents during
chemotherapy. Dacarbazine and Procarbazine are two known anti-cancer agents that
produce DNA methylation on N7 position of guanine.1
However, N7-Me-dG is difficult to study due to its short lifetime. This low
stability presents a challenge for chemists to prepare oligonucleotides containing N7-MedG using the standard phosphoramidite chemistry. The cationic base would have been
cleaved by nucleophiles at various stages if the standard phosphoramidite of 7-MeG were
to be synthesized. In addition, the N7-Me-G would not survive the oligonucleotide
deprotection conditions after the solid phase synthesis. On the other side, the fact that
these adducts are converted to more mutagenic products in cells makes the interpretation
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of in vivo mutagenic data problematic. Precise understanding of the mutagenic effects of
N7-Me-G is an important task for chemists and biochemists. This chapter describes the
chemical synthesis of stable analogues of N7-Me-G.

2.1.1 Biological Significance of N-Methyl and O-Methyl Adducts
Exposure of mammalian cells to methylating agents causes transfer of methyl groups to
N- as well as O-atoms of DNA bases. The structural and biological consequences of the
different N- and O-methyl adducts have been studied to various extents. Methylation at
oxygen atoms results in DNA lesions, especially O6-Me-G which has been shown to be
strong inducers of gene mutations.30 Yet many methylating agents react much more
frequently with nitrogen atoms than with oxygen atoms in the DNA, resulting in high
proportions of N7-Me-G and N3-Me-A in DNA adduct. Studies using DNA templates
treated with methylating agents and purified polymerases established the dogma that N7Me-G does not block replication and is perhaps not miscoding, but its depurination
produces an apurinic (AP) site, which if not repaired can be mutagenic and cytotoxic,
whereas N3-Me-A has been predicted as a replication fork blocking lesion. Structural
studies of DNA polymerases suggest that minor groove N3-purine and O2-pyrimidine
contacts are important during extension from newly synthesized base pairs, thus
providing an explanation as to why methyl groups at these positions would impede
polymerases.31
Methylation at the N3 site of adenine, which lies in the minor groove, has been
shown to result in cytotoxicity, but not mutations by high-fidelity polymerases.32 N3-MeA is cytotoxic by virtue of its ability to block replication and by virtue of its ability to
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give rise to a chemically or enzymatically generated AP site. Thus, compounds that can
generate exclusively N3-Me-A adducts can be used to destroy cells without any risk of
mutagenicity. For example, minor groove specific methylation reagent such as Me-Lex
has been suggested to play such a role.32 N3-Me-A is a quantitatively significant DNA
adduct formed from the reaction of many methylating agents. However, it is also in
combination with a large number of other DNA lesions, including N7-Me-G, O6-Me-G,
and N1-Me-A. In a previous study on the potential effect of N3-Me-A on DNA
replication, MMS and DMS, which predominantly react with DNA to produce N7-MeG, were used to methylate poly(dA-dT).33 Under these conditions, the heteropolymer
contained a mixture of N3-Me-A, N1-Me-A, and N7-Me-A adducts in a ratio of 16: 3: 1.
Replication of this template by E. coli DNA polymerase I decreased proportionally to the
level of total methyl lesions and/or abasic sites. The reduction of DNA polymerization is
likely to be caused by the N3-Me-A lesions.34 In contrast to error-free polymerases, in
vitro bypass study on a stable analogue of N3-Me-A showed that bypass polymerases
such as eukaryotic Y-family polymerases can efficiently replicate N3-Me-A, although
with significantly higher error rates.35
Unlike adenine, guanine methylation occurs mainly at the N7-position. Initially
N7-Me-dG (7MedG) was thought to be responsible for the high G→A transition rate
observed for the methylation of DNA. This assumption was indirectly supported by the
fact that

7Me

dG has a low pKa and should form a mispair with dT as a zwitterions.36

However, this became questionable when O6-methyl-dG, another guanine adduct that
induces G→A transitions, was discovered (see the next paragraph).37 Another
complication that N7-Me-dG brings is the secondary lesions. Ever since identification of
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the first N7-guanine adduct, several hundred studies on DNA adducts have been reported.
The instability of N7 purine adducts has prevented more through studies of these adducts
via site-specific approaches. Two hydrolysis pathways contribute to the instability of
N7-Me-dG

(Figure

2.2).

Hydrolysis

of

the

imidazole

ring

gives

FAPY

(Formamidopyrimidine) products which are weakly mutagenic. Studies have shown that
the ring opened methyl-formamidopyrimidine adduct of N7-Me-G can block E. coli DNA
polymerase Klenow fragment (Kf polymerase) in vitro,38,

39

However, the

misincorporation frequencies are significantly higher when error-prone polymerases are
used. Significant misincorporation of T was observed when N7-Me-FAPY-G was
bypassed by human polymerases η and pol κ.40 Hydrolysis of the glycosidic bond either
by a spontaneous process or an enzymatic repair mechanism gives AP site which is
known to have mutagenic and toxic consequences. Replication of AP sites by translesion
synthesis polymerases finishes with predominately deoxyadenosine incorporated.41 These
misinsertion events are responsible for the G→T transversions, the major mutations
observed for N7-Me-G adducts.

Figure 2.2 Hydrolysis pathways of N7-Alkyl-dG.
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On the other hand, oxygen-centered base methylation adducts are directly
mutagenic and much current evidence suggests that the most abundant of these, O6-MeG, plays a major role in mutagenesis and carcinogenesis. O6-Me-G mispairs with
thymine during DNA replication, which gives rise to a transition mutation of G:C to
A:T.37 The structure of O6-Me-G:T base pair was recently observed in a crystallography
study. Although O6-Me-G is readily replicated and does not produce secondary lesions, it
can be cytotoxic by being processed by MMR. This process results in long single-strand
patches; if that overlaps another O6-Me-G site of repair on the opposite strand, MMR can
generate double-strand disruptions or breaks.42 Other than O6-Me-G, O2-cytosine and
O4-thymine (Figure 2.3) can also react with methylation agents presumably because they
are not blocked by hydrogen bonding, and the extra pair of electrons available at oxygen
is free to react, even in a double-stranded form. O4-Me-T has been examined as a sitespecific adducts in mammalian vectors and appears to be more mutagenic than O6-MeG.43

Figure 2.3 Structures of DNA methylation lesions.
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In contrast, N1-adenine and N3-cytosine (Figure 2.3) are not very reactive toward
methylation reagents due to the hydrogen bonding participation, although these two sites
are much more susceptible to methylation in single stranded DNA. A more recent study
using site specific adducts in vectors passed through E. coli found that N3-Me-C was
more mutagenic than N1-Me-A, whereas both adducts blocked replication.20 The N1guanine and N3-thymine are secondary amines that have adjacent carbonyl groups and
are thus less reactive, the rare N1-Me-G and N3- Me-T (Figure 2.3) adducts were also
shown to be mutagenic and replication blocking.44
In summary, O-methylation products (e.g., O6-Me-G and O4-Me-T) are highly
mutagenic, whereas the mutagenicity of N-methylation products (e.g., N3-Me-A and N7Me-G) are weak but not clearly understood because of the possibilities of generating
secondary DNA lesions or recruiting error-prone polymerases. In general, the studies of
mutagenicity of DNA methylation adducts are challenging questions due to the
uncontrolled product distribution, the presence of secondary lesions, and the involvement
of multiple polymerases and repair enzymes.

2.2 Need for Stable Analogues of N7-Methyl-Guanine
The best way to precisely understand the mutagenic potential of a DNA lesion resulting
from misincorporation is to study the relative rate of dNTP incorporation by each
polymerase (See chapter 3). The low stability of N7-methylguanine becomes an obstacle
to synthesize oligonucleotides containing a single N7-methylguanine for the analysis of
DNA polymerase bypass. In fact, the only N7-alkylguanine that has been synthesized and
used for such a bypass study is the aflatoxin B1 (AFB1) N7-guanine adduct.45 Reaction
between guanine and AFB1 generates only one guanine adduct. Thus the method is not
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applicable to N7-methylguanines. Other reported synthetic N7-methylguanines were only
produced as randomly distributed mixtures, and more often together with other types of
low-abundance guanine adducts.46 The results were typically analyzed by looking into the
in vivo mutation map on a certain gene, or the composition percentage of digested
nucleotides after in vitro polymerase reactions. A problem of interpreting these data is
that many low-abundance guanine adducts are in fact much more mutagenic than N7methylguanines. Their contribution to the observed mutation is difficult to estimate. For
example, when methylation reagents such as NDMA and MMS react with guanine, O6methylguanine is also observed. Therefore researchers often attribute all observed G→A
transitions in vivo to the formation of O6-Me-G. This attribution is strongly backed by
the result of an in vivo study which showed the amount of O6-Me-G, not N7- Me-G,
correlated with the G→A transition events.37, 47, 48 However, the recent discovery that N7Me-FAPY-G, which is generated from N7-Me-G, may also causes G→A transitions has
made the interpretation more complicated.39,

40

In contrast to the well studied G→A

transitions, other guanine mutation were often overlooked or explained only by
speculations. For example, G→T transversions were explained by the formation of abasic
sites from N7-Me-G, although repair-enzyme knockout experiment results were
contradictory.49 Alternatively, G→T transversions were explained by the potential
mutagenic effect of N3-Me-G, which in fact was as poorly understood as N7-Me-G.50 In
addition, G→C transversions observed in Chinese hamster ovary cells were overlooked.51
Despite the ambiguity of the in vivo mutagenesis data, other indirect evidence does
support that N7-Me-G is non-mutagenic. First, thermal stability and structural studies of a
duplex DNA containing N7-Me-dG revealed that alkylation at the N7 position did not
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disrupt normal duplex formation.52, 53 This DNA duplex was synthesized by incorporating
the triphosphate of N7-Me-G. Similar single-stranded DNA containing N7-Me-G was not
reported, probably due to the difficulty to separate the two strands without the risk of
hydrolyzing the N7-Me-G. Second, nucleotide composition analysis of the replication
products of an RNA template containing randomly formed N7-methylguanosine showed
that N7-Me-rG did not increase the amount of UTP incorporated by RNA-dependent
RNA polymerase,46 although the margin of error determined that the best conclusion one
can draw is that N7-Me-rG is not very mutagenic on RNA replication.
In summary, N7-Me-G does not appear to have the tendency to incorporate
mismatched nucleosides at abnormally high frequencies. The N7 cationic charge does not
have significant impact on the ionic state of the base as was first proposed in the 1950’s.
However, the exact misincorporation frequencies opposite N7-Me-G would never be
determined if the technologies in synthesizing and handling unstable nucleosides remain
restricted.
2.3 Design of the Analogue N7-Methyl-Guanine
A stable analogue of an unstable DNA lesion can provide a good model to study its
various biophysical and biochemical properties. Huang and Greenberg54 previously made
structural analogues of oxidized abasic site and discovered that the analogues were
replicated in a way similar to the natural lesion. Verdine 55 reported N7-Me-2’-F-dG as a
stable analogue of N7-Me-dG and used it to trap 3-methyladenine DNA glycosylase II
(AlkA), the repair enzyme of N7-Me-G and N3-Me-A. However, the 2’-F group is
known to affect the polymerase activity and is not the best replacement in bypass
studies.56 Schärer57 recently used 7-deaza-dG as a stable analogue to study nitrogen
mustard interstrand cross-link. A similar strategy was used to replace N3-Me-dA by 3-
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Me-3-deaza-dA to study the bypass.35 The result showed 3-Me-3-deaza-dA was a
stronger blocker of error-free DNA polymerases. The same analogue was recently used to
trap AlkA for structural determination.58 These neutral isosteres of alkylated purines
should serve as the general replacement for structural or bypass studies. However, the Nglycosidic bond of these isosteres could be repaired by BER enzymes. For example, 7Me-7-deaza-G, a chemically stable analogue of N7-Me-G, can be removed by E. coli
BER enzyme Formamidopyrimidine [fapy]-DNA glycosylase (Fpg) (See chapter 4). It
was also discovered that 3-Me-3-deaza-A can be removed by AlkA.59

7Me9C

dG

7Me7C

dG

7C

dG

Figure 2.4 N7-Methyl-dG Analogues: N7-Methyl-9-deaza-dG (7Me9CdG), 7-Methyl-7deaza-dG (7Me7CdG), 7-deaza-dG (7CdG).

Hence, the best structural analogues of N7-methylguanine should fulfill the
following requirements.
1. The structure is stable and can be synthesized via the phosphoramidite chemistry.
2. The structure is stable against the actions of BER enzymes.
3. The structure is modular for the preparation of other N7-alkylG adducts for future
studies.
Finally, N7-methyl-9-deaza-dG (7Me9CdG) was selected as the analogue.7-Methyl7-deaza-dG (7Me7CdG) was also studied for the purpose of comparison (Figure 2.4).
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2.4 Synthesis of 7Me9CdG Phosphoramidite
This synthesis requires preparation of 9-deazaguanine which was originally prepared by
Gibson60 et al (Scheme 2.1). In their study, the synthesis of 9-deazaguanine was
synthesized by using the commercially available 2-amino-6-methylpyrimidin-4(3H)-one
as a starting material. The 9-deazaguanine was prepared in 5 steps. Nitration of starting
material afforded in compound 2. Treatment of 2 with N, N-dimethylformamide (DMF) dimethylacetal at room temperatures afforded the corresponding derivative 3. The
exocyclic amino group of 3 was protected with dmf (Dimethylformamide). The N1
Position of derivative 3 was protected with a benzyl group by treatment of benzyl
bromide in the presence of 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU), giving derivative
4. The 6-amino group of 4 was further protected with dmf at elevated temperature and
converted to derivative 5. Derivative 5 upon reductive cyclization was converted to N1benzyl-9-deazaguanine (6) in an 89% yield (Scheme 2.1).
The same strategy, with slight modifications, was used to synthesize our target
molecule (7) (Scheme 2.2). However, we experienced some difficulties in converting 5 to
6. All our attempts resulted in recovery of the starting material. In contrast to the original
synthesis in which they used a saturated solution of Na2S2O4 mixed with tetrahydrofuran
(THF) ,we found that the solubility of compound 5 was very low in the aqueous-THF
mixture, so we synthesized compound 6 using DMF as the co-solvent and at an elevated
temperature (65o C). Compound 6 was subjected to a methylation reaction using methyl
iodide as the reagent. The reaction initially proceeded poorly. Careful analysis of the 1H
NMR of the starting material suggested that it might have been difficult to remove
residual water from the previous reaction. However, even after drying compound 6 under
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high vacuum overnight, the reaction still suffer from low yields. Finally, it was proved
that this reaction was very sensitive to water and thus the solvent THF needs to be dried
under vigorous conditions. The yield was improved to 45% when THF was treated with
LiAlH4 under reflux conditions for more than 16 hours.

Scheme 2.1 Reported Synthesis of the Nucleobase 9CG.60 (a) H2SO4, HNO3, 50°C, 1
h,80%; (b) DMF-dimethylacetal,CH2Cl2, rt, 1 h,92%; (c) DMF , DBU, Benzyl bromide,
rt, 2 h,QY; (d) dry DMF, DMF-dimethylacetal 80oC, 8 h,93% (e) THF, Na2S2O4 , rt, 1
h,89%.
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Scheme 2.2: Synthesis of the Nucleobase 7Me9CG

Scheme 2.2 Synthesis of the Nucleobase 7Me9CG. (a) H2SO4, HNO3, 0°C, 3 h,88%; (b)
DMF-dimethylacetal,CH2Cl2, rt, 2 h,74%; (c) DMF , DIPEA, Benzyl bromide, r.t., 16
h,85%; (d) DMF, DMF-DMAC, 65oC, 4 h,70% (e) DMF, Na2S2O4 , 65oC, 2 h,84%; (f)
NaH, methyl iodide, dry THF, rt, 16 h, 45%.

The glycosyl donor 1-(a,b)-O-Methyl-3,5-di-(O-p-toluoyl)-2ʹ-deoxyribose was
prepared according to a reported procedure (Scheme 2.3).61 The commercially available
D-2-deoxyribose was treated with methanoic HCl which was generated in situ from
acetyl chloride and methanol. This reaction gave the O-methyl acetal of 2ʹ-deoxyribose.
The 5ʹ- and 3ʹ-hydroxyl groups of 2ʹ-deoxyribose were then protected with O-toluate by
the reaction with p-toluoyl chloride using DMAP as a catalyst.
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Scheme 2.3 Synthesis of Protected Methyl Glycoside of 2ʹ-deoxyribose. (a) D-2deoxyribose, CH3COCl, MeOH, rt, 4.5 h (b) DMAP, p-Toluoyl chloride, dry pyridine, rt,
16 h, 43% overall.

The C-glycosidic bond of N7-methyl-9-deaza-dG was formed via condensation of
7 and 8. SnCl4 was used as the Lewis acid to activate the O-glycosidic bond of 8, leading
to the formation of oxycarbenium ion, which underwent a Friedel-Crafts reaction with the
electron-rich C9 position of N7-methyl-9-deazaguanine. This reaction was affected by a
variety of factors (Table 2.1). In general, a 1:1 mixture of methylene chloride and
acetonitrile is a better solvent system than nitromethane, which was the solvent that
Gibson used to prepare 2ʹ-deoxy-9-deazaguanosine. The inclusion of methylene chloride
is critical as it increases the solubility of the starting material. The molecular ratio of
SnCl4 to the base also affected the yield. Larger amount of SnCl4 afforded significantly
higher yields. The optimal yield obtained in this reaction was 40%, much higher than that
reported by Gibson for the 2ʹ-deoxy-9-deazaguanine synthesis. This difference may be a
result of the electron-donating effect of the N7-methyl group. However, it is more likely
that reaction optimization contributed to the higher yield in our experiments. After
compound 9 was synthesized, the remaining steps were all protection and deprotection
reactions. Initially, we planned to use dmf as the protecting group for the exocyclic amine
for oligonucleotide synthesis, as it was already installed in the early stage of the
synthesis. Later, we found that dmf on compound 9 was very robust and could not be
removed even in 1:1 ethanol/concentrated ammonia at 80 °C for 48 h. Therefore
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deprotection of dmf would likely be problematic, if it were used for oligonucleotide
synthesis, although it was also possible that the adjacent benzyl group blocked the
hydrolysis. Incorporation of non-methylated 9-deaza-dG (9CdG) into oligonucleotides has
previously been reported on several occasions. Based on earlier studies we have changed
our synthesis route and thought of replacing dmf with an isobutyryl group to protect the
exocyclic amine. On the other hand, it was reported that C1 epimerization occurred
during the deprotection of isobutyramide of 9-deaza-dG in concentrated aqueous
ammonia at 55 °C for 12 h.62 One alternative solution was to use isopropylphenoxyacetyl
(iPac), a more base-labile protecting group, allowing deprotection in ammonia at room
temperature. However, another study on the deprotection of isobutyramide of a 2ʹ,3ʹdidehydro-2ʹ,3ʹ-deoxy nucleoside of 9-deazaguanine did not report obvious epimerization
even if the reaction was carried out in saturated ammonia in ethanol at 80 °C for 20 h.63
Therefore we decided to first try isobutyryl group for the protection of the exocyclic
amine of 7Me9CdG. (See later paragraph)

Table 2.1 Factors that Affected the Synthesis of 7-methyl-9-deaza-dG
Entry
1
2

SnCl4
(eqn.)
1.5
4

3
4
5

4
4
4

6

4

Solvent

Time(hr) Temp. % Yield

dry Nitromethane
dry Nitromethane

16 h
16 h

dry DMF
dry DCM
dry CH3CN
dry CH3CN :dry
DCM

o

0
10

4h
4h
4h

60 C
o
60 C
o
65 C
reflux
reflux

4h

reflux

44

0
0
0
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Scheme 2.4 Synthesis of 7Me9CdG Nucleoside. (a) Compound 8 SnCl4, 1:1 (v/v) dry
CH2Cl2–CH3CN, reflux, 4 h, 44%; (b)0.4 M KOH in 1:1 (v/v) H2O–EtOH, reflux, 16 h,
89%; (c) HCO2NH4, Pd/C, EtOH, reflux, 16 h, 46%.
The dmf group of 9 was successfully removed in 0.4 M methanoic KOH under
reflux conditions. No evidence for epimerization during deprotection was found. In the
next step, cleavage of the benzyl group under catalytic hydrogenation conditions with
Pd/C at 50 psi did not proceed. Substitution of Pd/C with the more reactive Pd (OH)2 /C
showed no improvement. A literature survey showed that the benzyl protecting on the N1
positions of hypoxanthine and guanine and the N3 positions of uracil and thymine 64, 65 is
difficult to remove under normal hydrogenolysis conditions. Successful transformation
requires a large amount of Pd34 catalyst or high temperature (over 100C)66. Concerned
upon the safety risks of using large quantities of Pd/C or higher temperature, we decided
to adopt catalytic transfer hydrogenation conditions. The first attempt to use 1, 4-
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cyclohexadiene as the hydrogen source was unsuccessful.67 Then ammonium formate
was used as the hydrogen source, which successfully removed the benzyl group. The
debenzylated compound 11 was obtained in 46% yield. TLC showed that starting
material was not completely consumed. Ultimately, extension of the reaction time or
adding more ammonium formate did not help improve the yield.

Scheme 2.5 Synthesis of 7Me9CdG Phosphoramidite. (a) TMSCl, Et3N, CH2Cl2, 0.5 h, then
isobutyric anhydride, dry pyridine, rt, 2 h, 68% (b) Dimethoxytrityl chloride, Et3N,
DMAP,
dry
CH2Cl2,
rt,
16
h,
60%;
(c)
2-cyanoethyl
N,Ndiisopropylchlorophosphoramidite, DIPEA, dry CH2Cl2, rt, 2 h, 48%.
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The phosphoramide of

7Me9C

dG (7) was then prepared using standard protocols

from 6.68 According to previous discussion, the exocyclic amine of the

9C

dG was

protected with an isobutyryl group. The compound 11 was converted to compound 12 via
transient protection. When we tested our methylated nucleoside 12, we also found that it
was fully deprotected and converted back to 11 in concentrated ammonia at 55 °C for 12
hours with no evidence of epimerization.
The 5ʹ-hydroxyl of 12 was protected as dimethoxytrityl (DMTr) ether. Initially we
used pyridine as the solvent. However, the pyridinium salts generated in the reaction comigrated with the starting material on the silica gel column, making recovery of
unreacted starting material difficult. Later we changed the solvent to methylene chloride.
This change was reproducible and unreacted starting material can be easily recycled for
same reaction. We found that the amount of DMAP and TEA has impact on the reaction
yield. Increase of the amount of TEA from 1.5 eq. to 2 eq. and DMAP from 0.05 eq. to
0.2 eq. resulted in improved yield (60%). The 3ʹ-hydroxyl was then activated as a
phosphoramidite through standard chemistry to yield the solid phase synthesis-ready
nucleotide 14. The commercially available phosphoramidites of 7Me7CdG and 7CdG, along
with 7, were incorporated into oligonucleotides: oligonucleotide 15, 16 (3ʹ- ACT CTG
TXC TTC GAT G-5ʹ, where X = dG, 7Me9CdG respectively), oligonucleotide 17, 18, 19
(3'-TAC CCT GCA CGA CAX AGT TTC AGC GGC ATG-5' where X = 7CdG , 7Me9CdG,
7Me7C

dG respectively) and 5ʹ-Fam labeled oligonucleotide 21, 22, 23 (3ʹ- TAC CTC TCT

TCC XTC CTA CGA ATG C-FAM-5ʹ where X = 7CdG , 7Me9CdG, 7Me7CdG respectively).
These oligonucleotides were used for the subsequent studies on thermal stability,
polymerase replication fidelity, and stability against enzymatic deglycosylation.
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2.4.1 Materials and Methods
All chemicals were purchased from Sigma-Aldrich or Fisher Scientific unless specified.
THF was dried over LiAlH4 and then distilled under Ar. CH2Cl2, pyridine, and
acetonitrile were distilled over CaH. Compound 7 was synthesized from 6methylisocytosine in five steps according to a reported procedure.60 The only
modification of the procedure was the last cyclization step where the solvent was
changed from THF to DMF due to the limited solubility of the starting material. NMR
spectra were recorded on a 300 MHz Bruker spectrometer. High resolution ESI-MS
spectra were obtained in the mass facility at Rutgers University (Newark, NJ).
Compound 2: To a mixture of 2-amino-6-methylpyrimidine-4(3H)-one (5 g, 40 mmol)
in 25 mL of H2SO4 at 0C was added 4 mL HNO3 with an additional funnel. After being
stirred at room temperature for 3 hr, the reaction mixture was slowly poured into 360 mL
of diethyl ether and stirred for 15min.The liquid was decanted and the remaining solid
was mixed 100 mL of ethyl acetate and was stirred for 10 h. The solid (6 g, 88% yield)
was filtered and used for next step without any further purification. 1H NMR (300 MHz,
DMSO-d6) δ ppm 2.26 (d, J=1.40 Hz, 3 H).

Compound 3: To a suspension of 2 (6 g, 35 mmol) in methylene chloride (106 mL)
DMF-dimethylacetal (12.1 mL) was added and the mixture was stirred at room
temperature for 1.5 hour. The precipitated product was removed by filtration to give 3
(5.86 g, 74%). 1H NMR (300 MHz, DMSO-d6) δ ppm 2.27 (s, 3 H) 3.08 (s, 3 H) 3.21 (s,
3 H) 8.73 (s, 1 H).
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Compound 4: To a suspension of compound 3 (6.55 g, 29 mmol) in DMF (143 mL),
N, N-diisopropylethylamine (DIPEA) (4.70 g, 36.4 mmol) was added and the reaction
mixture became clear. To this solution was added benzyl bromide (15.66 g, 92 mmol,
over 1 h) and the mixture was stirred at room temperature overnight. The residue was
dissolved in methylene chloride (200 mL). The solution was washed with sat. solution of
NaHCO3 (3 x 100 mL), dried MgSO4 and concentrated. Trituration with methanol (150200 ml) to give 4 (7.72 g, 85%). 1H NMR (300 MHz, CHLOROFORM-d) δ ppm 2.43 (s,
2 H) 3.22 (s, 3 H) 3.30 (s, 3 H) 5.44 (s, 2 H) 7.23 - 7.36 (m, 3 H) 7.42 - 7.50 (m, 2 H)
8.78 (s, 1 H).

Compound 5: To a suspension of compound 4 (7.72 g, 25 mmol) in DMF (30 mL) at
65C DMF-DMAC (4.41mL) was added and the mixture was stirred at this temperature
for 3-4 h until TLC analysis showed disappearance of the substrate. Concentration and
trituration of the residue with methanol (150 mL) resulted in 5 (6.57 g, 70%). 1H NMR
(300 MHz, CHLOROFORM-d) δ ppm 3.06-3.21 (m, 12 H) 5.36 (s, 2 H) 5.66 (d, J=12.21
Hz, 1 H) 7.18 - 7.29 (m, 3 H) 7.40 (d, J=6.68 Hz, 2 H) 7.90 (d, J=12.21 Hz, 1 H) 8.57 (s,
1 H).

Compound 6: To a stirring solution of 5 (3.2 g, 8.6 mmol) in DMF (66 mL) maintained
at 60-65C was added sodium dithionite (Na2S2O4, 23 g). Distilled water was added (180
mL) gradually portion wise to this solution during a period of 30 min, until an orange
yellowish solution was obtained and color lightened. The reaction mixture was cooled to
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room temperature and the yellowish white precipitate was collected by filtration and then
washed with water to give 6 (2.11 g, 84%). 1H NMR (300 MHz, CHLOROFORM-d) δ
ppm 3.06 (s, 3 H) 3.11 (s, 3 H) 5.61 (s, 2 H) 6.28 (t, J=2.50 Hz, 1 H) 7.10 (t, J=2.93 Hz, 1
H) 7.17 - 7.32 (m, 4 H) 7.38 - 7.44 (m, 2 H) 8.48 (s, 1 H).

Compound 7. To a stirring solution of compound 6 (0.610 g, 2 mmol) in dry THF (40
mL) was added sodium hydride (83mg, 2 mmol). The reaction was stirred for 10 min
before iodomethane (2.90 g, 20 mmol) was added at 0C. The mixture was stirred at
room temperature overnight. The reaction was diluted with methylene chloride and
washed successively with sat.NaHCO3 and brine. The organic layer was separated, dried
over MgSO4, and filtered. The filtrate was concentrated. The residue was
chromatographed on a column of silica gel eluted with 3:2 hexane/ethyl acetate to give
compound 7 (275 mg, 45%). 1H NMR (300 MHz, CDCl3) δ ppm 3.03 (s, 3 H), 3.09 (s, 3
H), 4.04 (s, 3 H), 5.52 (s, 2 H), 6.20 (d, J=3 Hz, 1 H), 6.93 (d, J=3 Hz, 1 H), 7.15-7.30
(m, 3 H), 7.38 (d, J=7 Hz, 2 H), 8.47 (s, 1 H).

13

C NMR (75 MHz, CDCl3) δ ppm 34.9,

35.6, 40.7, 45.1, 100.7, 115.0, 126.6, 127.8, 128.0, 131.3, 139.0, 144.3, 154.1,
156.1. ESI-MS (M+ H+) for C17H19N5O: expected 310.1662, found 310.1662.

Compound 9. To a suspension of compound 7 (0.914 g, 2.95 mmol) and 1-(α, β)-Omethyl-3,5-di-(O-p-toluoyl)-2ʹ-deoxy-D-ribose(compound 8) (1.36 g, 3.54 mmol) in a
mixture of methylene chloride (12 mL) and acetonitrile (12 mL) was added a solution of
SnCl4 in methylene chloride (1 M, 11.82 mL, 11.82 mmol). The reaction mixture was
heated at reflux for 3-4 h until TLC analysis showed disappearance of the nucleobase.
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The reaction mixture was diluted with methylene chloride and washed successively with
sat.NaHCO3 and brine. The organic layer was separated, dried over MgSO4, and filtered.
The filtrate was concentrated. The residue was chromatographed on a column of silica gel
eluted with 1:1 hexane/ethyl acetate to give compound 9 (0.840 g, 44 %). 1H NMR (300
MHz, CDCl3) δ ppm 2.37-2.51 (m, 8 H), 3.01-3.07 (m, 3 H), 3.11 (s, 3 H), 3.99 (s, 3H),
4.49-4.62 (m, 2 H), 4.65-4.74 (m, 1 H), 5.48-5.58 (m, 2 H), 5.75-5.81 (m, 1 H), 6.95 (s, 1
H), 7.17-7.33 (m, 8 H), 7.39 (d, J=7 Hz, 2 H), 7.98 (dd, J=17, 8 Hz, 4 H), 8.56 (s, 1 H).
13

C NMR (75 MHz, CDCl3) δ ppm 21.1, 34.4, 35.0, 37.5, 40.2, 44.5, 64.0, 72.9, 76.5,

81.2, 112.6, 115.0, 126.1, 126.5, 127.0, 127.2, 128.5, 129.1, 129.6, 138.4, 141.7, 143.1,
143.4, 153.4, 155.6, 156.0, 165.6, 165.8. ESI-MS (M+ H+) for C38H39N5O6: expected
661.2900, found 662.2919.

Compound 10. A suspension of 9 (0.430 g, 0.66 mmol) in 0.4 M potassium hydroxide
in a mixture of ethanol and water (1:1, 10 ml) was heated under reflux overnight and
allowed to cool to room temperature. The reaction mixture was evaporated to dryness.
The residue was chromatographed on a column of silica gel with 5% methanol in ethyl
acetate to give 10 (220 mg, 89%). 1H NMR (300 MHz, CD3OD) δ ppm 2.03 (dd, J=13, 6
Hz, 1 H), 2.36-2.52 (m, 1 H), 3.62-3.71 (m, 1 H), 3.74-3.83 (m, 1 H), 3.93 (s, 3 H), 3.99
(br, 1 H), 4.43 (d, J=5 Hz, 1 H), 5.20-5.32 (m, 3 H), 7.13-7.37 (m, 6 H). The 1H NMR in
CDCl3 showed a different spectrum which indicates the formation of an intramolecular
hydrogen bond between the benzyl C-H and the exocyclic amine.

13

C NMR (75 MHz,

CD3OD) δ ppm 35.9, 43.7, 45.2, 64.9, 75.9, 76.3, 89.5, 114.4, 114.7, 127.7, 128.7, 129.9,
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133.1, 137.4, 144.2, 152.6, 156.6. ESI-MS (M+H+) for C19H24N4O4: expected 371.1714,
found 371.1729.

Compound 12. To compound 10 (304 mg, 0.82 mmol) and 10% palladium on carbon
(600 mg) in ethanol was added ammonium formate (504 mg, 8 mmol) under Ar. The
reaction mixture was heated under reflux overnight and then filtered through Celite. The
filtrate was evaporated to dryness. The residue was chromatographed on a column of
silica gel with 12% methanol in ethyl acetate to give 5 (106 mg, 46%). 1H NMR (300
MHz, CD3OD) δ (ppm) 1.89- 2.02 (m, 2H), 2.35 (ddd, J=13, 11, 5 Hz, 1H), 3.60-3.68 (m,
1H), 3.71-3.78 (m, 1H), 3.86 (s, 3H), 3.94 (d, J=1 Hz, 1 H), 4.04 (q, J=7 Hz, 1H), 4.38
(d, J=5 Hz, 1H), 5.19 (dd, J=11, 5 Hz, 1H), 7.05 (s, 1 H). Compound 11 (144 mg, 0.54
mmol) was co-evaporated with anhydrous pyridine (6 mL) three times and dried under
vacuum overnight. It was then dissolved in pyridine (4 mL). TMSCl (0.7 mL, 5.4 mmol)
was added slowly to the suspension in an ice bath. After 30 min, Isobutyric anhydride
(0.45 ml, 2.7mmol) was added and the mixture was stirred for 2.5 h at room temperature.
The reaction mixture was then chilled in an ice bath; 5 mL of cold water was added and
the mixture was stirred for 15 min before con. aqueous ammonia (5 mL) was added. The
reaction was stirred for another 30 min and the volatiles were the removed under reduced
pressure. The residue was re-dissolved in dichloromethane and purified by column
chromatography using 2% MeOH in ethyl acetate as the eluent to give 12 (111 mg, 58%).
1

H NMR (300 MHz, CDCl3) δ ppm 1.16-1.32 (m, 6H), 1.16-1.21 (m, 2H), 2.02-2.13 (m,

1H), 2.43-2.76 (m, 2H), 3.70-3.79 (m, 1H), 3.87-3.96 (m, 1H), 3.98-4.07 (m, 3H), 4.12
(s, 1H), 4.60 (d, J=5 Hz, 1H), 5.27 (dd, J=11, 5 Hz, 1H), 6.97 (s, 1H).
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C NMR (75

38
MHz, CDCl3) δ ppm 19.0,19.1, 35.7, 36.3, 36.3, 43.4, 64.1, 74.8, 75.6, 88.2, 114.6,
116.5, 130.4, 140.8, 144.5, 153.2, 178.6. ESI-MS (M+H+) for C16H22N4O5: expected
351.1663, found 351.1604.

Compound 13. Compound 12 (104 mg, 0.3 mmol) was dried by coevaporation with
anhydrous pyridine. The residue was suspended in anhydrous dichloromethane (6 mL),
followed by the addition of dry triethylamine (80 µL, 0.6 mmol). A solution of 4, 4’dimethoxytrityl chloride (121 mg, 0.36 mmol) and DMAP (7 mg, 60 µmol) in
dichloromethane was added and the reaction mixture was stirred at room temperature
overnight before it was quenched by adding 0.1 mL MeOH. The reaction was diluted
with dichloromethane and washed successively with sat.NaHCO3 and brine. The organic
layer was dried over anhydrous MgSO4 and filtered. The solvent was removed in vacuo.
The crude product was purified via flash silica gel column chromatography eluted with
hexane/ethyl acetate/triethylamine (10%:88%:2%) to give the dimethoxytrityl ether of 13
(123 mg, 60%) as a white foam. 1H NMR (300 MHz, CDCl3) δ ppm 0.84-1.03 (m, 3H),
1.09-1.31 (m, 3H), 1.91-2.11 (m, 3H), 2.19 (dd, J=13, 5 Hz, 1H), 3.08-3.20 (m, 1H),
3.23-3.40 (m, 2H), 3.72-3.82 (m, 6H), 3.99 (s, 3H), 4.04-4.17 (m, 1H), 4.58 (d, J=5 Hz,
1H), 5.35 (dd, J=11, 5 Hz, 1H), 6.78 (dd, J=9, 4 Hz, 4H), 6.98 (s, 1H), 7.15-7.31 (m, 4H),
7.34- 7.44 (m, 3H), 7.52 (d, J=7 Hz, 2H). 13C NMR (75 MHz, CDCl3) δ ppm 18.6, 18.7,
35.7, 36.1, 41.0, 55.2, 72.7, 74.7, 86.0, 113.1, 115.0, 115.9, 126.8, 127.8, 128.2, 130.1,
130.4, 136.1, 136.4, 142.4, 143.9, 145.2, 153.5, 158.5, 178.2, 178.17. ESI-MS (M+Li+)
for C37H40N4O7Li: expected 659.3052, found 659.3114.
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Compound 14. A solution compound 13 (86 mg, 0.13 mmol), diisopropylethylamine (91
µL, 0.52 mmol), and 2-cyanoethyl N,N’-diisopropylchloro phosphoramidite was stirred
for 2 h at room temperature under argon. The reaction was quenched with 0.1 mL MeOH
and concentrated in vacuo. The crude material was purified by silica gel chromatography
using hexane/ethyl acetate (1:1) as the eluent to yield 14 (54 mg, 48%) as a white foam.
1

H NMR (300 MHz, CDCl3) δ ppm 1.08 (d, J=7 Hz, 1H), 1.12-1.21 (m, 12H), 1.49 (d,

J=7 Hz, 6H), 1.65 (s, 4H), 2.45 (t, J=7 Hz, 1H), 2.68 (d, J=7 Hz, 1H), 3.70 (d, J=7 Hz,
1H), 3.77 (br, 9H), 4.02 (s, 4H), 4.05-4.17 (m, 4H), 6.78 (m, 4H), 7.03 (s, 1H), 7.16-7.30
(m, 8H), 7.44 (s, 1H). 31P NMR (121 MHz, CDCl3) δ ppm 148.4, 149.0. ESI-MS (M+Li+)
for C37H40N4O7Li: expected 859.4131, found 859.4237.

2.4.1.1 DNA Synthesis and Purification
Oligonucleotide 20 was purchased from Integrated DNA Technologies (Coralville, IA).
Other oligonucleotides were synthesized on an ABI 394 DNA synthesizer. The
phosphoramidites of Bz-A, dmf-G, Ac-C, T,

7C

dG, and 5’-FAM were purchased from

Glen Research Corporation (Sterling, VA). The phosphoramidite of

7Me7C

dG was

purchased from Berry and Associates, Inc. (Dexter, MI). The coupling time of modified
phosphoramidites was extended to 15 min. Oligonucleotides were deprotected in
concentrated ammonia at 55 °C for 12 h. The crude oligonucleotides were purified by
20% denaturing PAGE. The gel band that contained the desired oligonucleotide was cut,
crushed, and soaked in a solution of 100 mM NaCl and 1 mM EDTA overnight. The
extract was centrifuged and the supernatant was desalted using a C-18 Sep-Pak cartridge
(Waters). The concentrations of DNA were quantified using UV absorbance at 260 nm on
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a Shimadzu UV-1700 spectrometer. High-resolution ESI-MS spectra of oligonucleotides
were obtained in Rutgers University (Newark) mass facility after precipitation in 2.5 M
ammonium acetate solution.
Oligonucleotide 18 (3'-TAC CCT GCA CGA CAX AGT TTC AGC GGC ATG-5'),
calculated, 9198.5396 (M+H), found, 9198.7096;
Oligonucleotide 16 (3’- ACT CTG TXC TTC GAT G-5’), calculated, 4871.8264 (M+H),
found, 4875.9163;
5’-Fam labeled oligonucleotide 22 (3’- TAC CTC TCT TCC XTC CTA CGA ATG CFAM-5’), calculated, 8072.7111 (M+Na), found, 8073.5228.

2.5 Thermal Stability of Duplex DNA Containing N7-methyl-9-deaza-dG
2.5.1 UV Melting Temperatures
Duplex DNAs (50 μM for each strand) were hybridized in 100 mM NaCl, 10 mM
MgCl2, and 10 mM piperazine-N,N′-bis(2-ethanesulfonic acid) (PIPES) buffer (pH 7.5).
A solutions of the DNA duplex (1-5 μM) containing 20 mM NaCl, 2 mM MgCl2, and 10
mM PIPES (pH 7.5) in a total volume of 100 μL was heated from 15 to 85°C at 1°C/min.
UV absorbance at 260 nm was taken every 1°C. The melting temperatures were
calculated from the first derivative of the curve using the LabSolution software.
Experiments were performed in triplicate. ΔH and ΔS were derived from Van't Hoff plots
using the equation 1/Tm = (R/ΔH)ln[C]total + (ΔS-Rln4)/ΔH. [C]total is the total
concentration of the two DNA strands.
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2.5.2 Results and Discussion
The melting temperatures of duplex DNA 15-16 were measured to study the impact of
7Me9C

dG on the thermal stability of duplex DNA. The results showed that the duplex

melting temperature (Tm) was lowered slightly by 1.3 °C in the presence of

7M9C

dG when

the duplex concentration was 5 μM. This small difference of Tm (7M9CdG) is unlikely to
affects the polymerase fidelity significantly. Previous study by Verdine et al. on duplex
DNA containing

7Me

dG showed that

7Me

dG also lowered melting temperature of duplex

DNA.53 In that study, the melting temperature drop was mainly caused by the entropy
effect. In fact,

7Me

dG contributes to a stronger duplex in the enthalpy change. Study on

duplex DNA containing

7Me7C

dG, on the other hand by Seela et al. showed that

7Me7C

dG

contributes to a slightly weaker duplex in the enthalpy change.69 Replacement of dG with
7Me7C

dG caused a decrease of 0-0.5 kcal/mol in ΔH per substitution, depending on the

sequence.
To get a deeper understanding of thermal denaturation experiment, we obtained
the thermodynamic parameters of the duplex formation (Table 2.1). The enthalpy change
(ΔH°) of duplex formation was made significantly more favorable by the presence of
7Me9C

dG. The base pairing stability of 7Me9CdG:dC showed an increase of 5.7 kcal/mol in

enthalpy change. The different influences of base pairing of 7Me7CdG: dC and 7Me9CdG:dC
on the enthalpy change of duplex formation could result from a variety of reasons.
Structurally both bases contain a 7-methyl group and lack the N7 lone pair which is
important for water binding. The 7-methyl group positively contributes to the stacking
energy and should increase the stability of the duplex to a similar extent. However, The
loss of the N7 binding site is expected to decrease the stability of the duplex, 70 but the
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amount of decrease should also be similar. Other differences between the two structures
might be that the two base pairs may be different in hydrogen bonding energies or sugar
ring conformations. The hydrogen bonding energy between 7,9-dimethyl-9-deazaguanine
and 1-methylcytosine is 2.1 kcal/mol smaller than that between 7,9-dimethyl-7deazaguanine and 1-methylcytosine, according to a computational study conducted by
our group. Therefore hydrogen bonding energy predicted a result opposite to the
experimental observation. The other explanation based on sugar ring pucker is more
reasonable due to the fact that C-nucleosides prefer the 3’-endo conformation, as opposed
to the 2’-endo conformation expected for N-nucleosides.64
Despite the favored sugar ring conformation for duplex formation, the less
favorable entropy change (ΔS°) contributed predominantly to destabilize duplex DNA.
This observation is similar to the result of 7MedG52, although the impact of entropy change
observed for

7Me

dG was more dramatic. At room temperature, replacement of dG by

7Me

dG resulted in an increase in duplex stability (-ΔG298), while replacement by

rendered the duplex less stable.

7M9C

dG
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Table 2.2 Thermodynamics of the Formation of Duplex DNA Containing 7M9CdGa
5’- TGA GAC ACG AAG CTA C-3’
3’- ACT CTG TXC TTC GAT G-5’
15, X = dG
16, X = 7Me9CdG

Duplex

b

Tm (°C)

ΔH (kcal/mol)

ΔS (cal/mol K)

ΔG298
(kcal/mol)

15

61.1

-116.2

-322

-20.3

16

58.8

-121.9

-345

-19.2

a. Buffer conditions: 20 mM NaCl, 2 mM MgCl2, 10 mM PIPES (pH 7.5).
b. Measured at 5 µM duplex concentrations.

CHAPTER 3
REPLICATION OF N7-METHYL-9-DEAZA-DG AND 7-METHYL-7-DEAZA-DG
BY KLENOW FRAGMENT (EXO-) OF E. COLI DNA POLYMERASE I.

3.1 Background Information
DNA is considered to be “the molecule of life” since it contains the genetic blueprint for
all organisms. The ability to accurately and efficiently duplicate DNA is essential for the
survival and proliferation of any organism. The process of replicating an organism’s
genomic material is complex and requires the coordinated efforts of an ensemble of
proteins to initiate, propagate, and terminate each biochemical event in a timely and
orderly fashion.71 At the core of the replication process is the DNA polymerase, the
enzyme that catalyzes the incorporation of mononucleotides into a growing polymer
(primer) using a DNA template as a guide for directing each incorporation event. The
newly-polymerized molecule is complementary to the template strand and identical to the
template's original partner strand. During this process, the polymerase maintains an
incredible degree of selectivity to insert only one of four potential deoxynucleoside 5′triphosphates (dNTPs) opposite a template base while possessing an extraordinary degree
of flexibility to recognize four distinct pairing partners. DNA polymerases strictly follow
the Watson-Crick base-pairing rules, with cytosine and guanine always forming a pair
and thymine and adenine always forming a pair. The fidelity of a DNA polymerase is the
result of accurate replication of a desired template. Specifically, this involves multiple
steps, including the ability to read a template strand, select the appropriate nucleoside
triphosphate and insert the correct nucleotide at the 3´ primer terminus, such that Watson-
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Crick base pairing is maintained. In addition to effective discrimination of correct versus
incorrect nucleotide incorporation, some DNA polymerases possess a 3ʹ→5ʹ exonuclease
activity. This activity, known as “proofreading”, is used to excise incorrectly
incorporated mononucleotides that are then replaced with the correct nucleotide. The
function of DNA polymerase is not quite perfect, with the enzyme making about one
mistake for every billion base pairs copied, even with the assist of proof-reading ability.

Figure 3.1 Cartoon depiction of DNA Polymerase Structure.

The known DNA polymerases have highly conserved structures. The shape can be
described as resembling a right hand with thumb, finger, and palm domains (Figure 3.1).
The palm domain appears to function in catalyzing the transfer of phosphoryl groups in
the phosphoryl transfer reaction. DNA is in the palm when the enzyme is active. The
finger domain functions to bind the nucleotide triphosphate with the template base. The
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thumb domain plays a potential role in the processivity, translocation, and positioning of
the DNA.72 DNA polymerase can add free nucleotides to only the 3ʹ end of the newlyforming strand. This results in elongation of the new strand in a 5ʹ→3ʹ direction. No
known DNA polymerase is able to begin a new chain (“de novo”); therefore replication
requires a primer at which it can add the first nucleotide (Figure 3.2). The 3ʹ-OH group
forms a bond to the phosphorous atom of the free nucleotide closet to the 5ʹ-O atom. A
new phosphodiester bond now joins the two nucleotides. A pyrophosphate group (PPi) is

DNA Polymerase

Extension

2ppi

Figure 3.2 Cartoon depiction of DNA Polymerase Processivity.
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liberated during the formation of the phosphodiester bond. The pyrophosphate is
hydrolyzed, releasing a great deal of energy and driving the reaction forward to
completion. Otherwise the pyrophosphate can inhibit the enzyme turnover.
DNA polymerases are divided into seven families based on their sequence
homology and crystal structure analysis. These include families A, B, C, D, X, Y and RT.
Error-free (high-fidelity) lesion bypass and error-prone (low-fidelity) lesion bypass are
important cellular responses to DNA damage during replication, both of which require a
DNA polymerase. A high fidelity DNA polymerase, such as those in the A, B, and C
families, has a very low error rate in incorporating correct nucleotides into the newly
synthesized DNA strand. It follows the mechanism contributes to the selection of correct
dNTP by Watson–Crick base pairing. While the low fidelity DNA polymerase, such as
those in the X and Y families, incorporates non-Watson-Crick base-paired nucleotides
into a growing DNA strand with relatively high frequency. High fidelity DNA synthesis
is beneficial for maintaining genetic information. When a DNA lesion disallows a highfidelity polymerase to incorporate the correct nucleotide, replication stalls to avoid
mutations. However, this may lead to cytotoxicity. In case of emergency, low-fidelity
polymerases can be recruited to bypass the lesion, with a compromise of losing fidelity.
In this work, DNA polymerase I (Pol I), a high-fidelity polymerase in prokaryotic
cells, was used to examine the effects of the N7-methyl group of N7-Me-dG. DNA pol I
obtained from E. coli is used extensively for molecular biology research. Discovered by
Arthur Kornberg in 1956,73 pol I possesses following enzymatic activities : the 5'→3'
(Polymerase) activity, and both the 3'→5' exonuclease (Proofreading) and the 5'→3'
exonuclease activities (RNA Primer removal). However, the 5'→3' exonuclease activity
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makes it unsuitable for many applications. Fortunately this undesirable enzymatic activity
can be simply removed from the holoenzyme to leave a useful molecule called the
Klenow fragment, widely used in molecular biology. The Klenow fragment is a large
protein fragment produced when DNA polymerase I from E. coli. It retains the 5'→ 3'
polymerase activity and the 3ʹ→5ʹ exonuclease activity for removal of precoding
nucleotides and proofreading, but loses its 5'→ 3' exonuclease activity. Just as the 5' →3'
exonuclease activity of DNA polymerase I from E.coli can be undesirable, the 3' → 5'
exonuclease activity of Klenow fragment can also be undesirable for certain applications.
This problem can be overcome by introducing mutations in the gene that encodes
Klenow. These results in forms of the enzyme being expressed that retain 5' → 3'
polymerase activity but lack any exonuclease activity (5' → 3' or 3' → 5'). This form of
the enzyme is called the exo- Klenow fragment (Kf (exo-)).

3.1.1 Mechanism of DNA Polymerization and Methods in the Measurement of DNA
Polymerization Efficiency and Fidelity
Kinetic mechanism for most DNA polymerases follows these steps (Figure 3.2). Step 1 is
the binding of polymerase (E) to DNA substrate. Step 2 involves dNTP binding to the
polymerase/DNA complex. Step 3 represents a conformational change in the polymerase:
DNA complex that is followed by phosphoryl transfer (Step 4). After the nucleotide is
covalently added to the growing primer, there is a conformational change step in the
polymerase that relaxes the E′:DNAn+1:PPi to the E:DNAn+1:PPi species (Step 5).
Following this step, PPi is released as the first product from the polymerase (Step 6). At
this stage, the polymerase can remain bound to the product DNA (DNAn+1) to continue
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synthesis on the same nucleic acid substrate or dissociate from the DNAn+1 to renew
polymerization on another substrate.
Maintaining fidelity during DNA replication is challenging since the changing
nature of the heteropolymeric DNA template places strain on the unusually high demand
for substrate specificity. The hydrogen bonding interactions explain how each
incorporation event occurs efficiently and selectively. The molecular events underlying

Figure 3.3 Kinetic mechanisms for most DNA Polymerases.74

reductions in misincorporation rates are typically interpreted with respect to perturbations
in the formation of correct hydrogen bonds between the incoming dNTP and its
mismatched partner. Simply put, the rates for misincorporating a dNTP are slow since the
functional groups required for proper Watson-Crick interactions do not line up properly.
Unfortunately, the nucleobases that provide favorable hydrogen bonding interactions are
reactive and thus, susceptible to modifications that can influence the mechanism and
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fidelity of DNA polymerases. Methylating agents such as MMS and MNNG
preferentially react with the N3 and N7 positions of adenine and the O6 and N7 position
of guanine.2 Methylation at the O6 position of guanine changes the hydrogen bonding
capabilities, which increases the frequency of misincorporation events. In addition,
methylation at the N7 position destabilizes the N-glycosidic bond leading to spontaneous
depurination of this lesion and result abasic sites by nonenzymatically or via the actions
of various DNA glycosylases (Discussed in next chapter). The abasic sites are strong
blockers of high-fidelity DNA polymerases due to the lack of hydrogen-bond-forming
nucleobases.
It is well-established that a cancer cell is genetically different from its normal
counterpart. Changes in genetic composition and context can occur by mutagenic events
that are caused by inappropriate and/or dysfunctional DNA replication. To understand
these mutagenic events, we need to examine how defects in DNA affect the activity and
fidelity of polymerases, which contributes to the initiation and progression of cancer. A
powerful approach toward understanding the mechanism of mutagenesis is to compare
the catalytic efficiency of DNA polymerases for the incorporation of a correct (e.g.,
dGTP opposite cytosine) versus an incorrect (e.g., dGTP opposite thymine) nucleotide
triphosphate.
In this chapter, the study of in-vitro mutagenesis on modified bases can be
achieved from steady-state enzyme kinetic analyses. In these assays, a primer template
complex is mixed with a polymerase and a dNTP. The primer is end-labeled with a
fluorophore (5’-Fam). The reaction is run for a fixed amount of time (to keep the amount
of product ≤ 30% to avoid “multiple hits”, i.e., that each primer-template associates with
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and dissociates from polymerase multiple times). The nucleotide insertion velocity (ν0) at
the lesion site, given by the ratio of the integrated intensities of primers extended to the
target site (and beyond) compared with the integrated intensity of primers extended to a
site just prior to the target, was calculated for each [dNTP]. Velocities were calculated
by using the equation75 ν0 = I/ (I0+0.5I) t , where I0 (DNAn) and I ( DNAn+1) ( Figure
3.3a) are gel band intensities after t sec of reaction time. I is the amount of product
formed, I0 is the amount of starting material. The maximum magnitude of I was
controlled by adjusting the concentrations of dNTPs in the reactions and the reaction
times. The velocity reflects the slowest step among polymerase association with primertemplate, substrate-initiated conformational change, formation of the phosphodieseter
bond, dissociation of pyrophosphate, and dissociation and reassociation with a different
primer-template. Treatment of the reaction with inorganic pyrophosphatase guarantees
that pyrophosphate release is not the rate-determining step. The most likely rate
determining step is the nucleotide incorporation step, particularly when mismatched
nucleotide triphosphates are involved. The velocities for the incorporation of one
nucleotide at a time vs dNTP concentration can be fit into the Michaelis-Menten equation
(Equation 1).

The apparent steady-state kinetic parameters (Km and Vmax) for the incorporation of the
correct and incorrect nucleotides can be determined by the fitting. The k cat values were
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then calculated by dividing the Vmax values with the concentration of the polymerase
used. The efficiency of nucleotide incorporation was determined by the ratio of kcat/Km.

The fidelity of nucleotide incorporation fmis (misinsertion efficiency) was determined by
the taking ratios of (Equation 3.2) incorrect to correct insertions i.e., the base normally
pairing with the base that was modified (e.g. C with, N7-Me-G) for each of the four
dNTPs.
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3.2 Experimental

(a)

(b)

Velocities (%.Sec-1)

dNTP Concentration (nM)

Figure 3.4 Polymerase assays. (a) PAGE analysis of Gel band intensity versus dNTP
substrate concentration. The colors of the gel images were inversed for clarity. (b)
Michaelis-Menten curves were obtained by using Origin 8.1.Reactions and product
analyses were performed as described in 3.2"Polymerase Assays". All values are the
averages of three independent experiments.
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DNA templates 17-19 (50 μM) were hybridized in equal molar ratio with the 5’Fam labeled primer in a solution of 12.5 mM NaCl and 12.5 mM Tris-HCl (pH 7.5). Kf
(exo-) (New England Biolab, 0.320–20 nM) was incubated with inorganic
pyrophosphatase (New England Biolab, 1.5 mole equiv.) in a 80 μL solution containing 1
mg/mL BSA, 5 mM NaCl, 1 mM Tris-HCl, 1 mM MgCl2, and 100 nM DTT (pH 7.9) at
25°C for 10 min. the enzyme solution was mixed with 80 μL of dNTP of different
concentrations, which range from about 0.3Km to 3Km. After an appropriate amount of
time (3-15 min, depending on the type of dNTP), the reaction were stopped by adding 40
µL of 90% formamide loading buffer. The mixture was concentrated and loaded to 20%
denaturing PAGE (Figure 3.4).
The gel was visualized using AlphaImager® EP with a liner dynamic range of
4096 gray scale. The intensities of the primer and extension bands were quantified using
Alphaview 3.0. When dTTP was used, multiple extension bands were observed. The total
intensity of these bands was used for calculation. The reaction rates were calculated
according to ν0 = I/(I0+0.5I)t. Michaelis-Menten curves were generated using values
obtained from the averaging of at least three replicates using Origin 8.1 (Figure 3.4).

3.3 Results and Discussion of Polymerase Assays
Bypass of
7Me7C

7Me9C

dG by the Klenow fragment of E. coli Pol I together with

7C

dG and

dG was studied in vitro. Single-nucleotide insertion experiments were performed

using the standing start kinetic study of dNTP incorporation on a DNA template
containing a single

7Me9C

dG or

7Me7C

dG. In a crystal structure of Kf (exo-)/duplex DNA

cocrystallized with ddCTP (PDB 2HVI) (Figure 3.4), hydrogen bond was observed
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between the N7-position of guanine in the template. Hydrogen bonding plays crucial role
in the process of DNA polymerization. The N7 nitrogen of dG is very different from all
the N7-methyl compounds61,
metal ions.

76-84

due to its ability of bind water molecule or divalent

Hence, we have used

7C

dG instead of dG for comparison in order to

separately investigate the influences of the additional methyl group and the loss of the N7
binding site. We have performed single-nucleotide insertion experiments under steadystate conditions and oligonucleotides 17-19 were used as the templates.

Figure 3.5 A Crystal structure of Kf (exo-)/duplex DNA cocrystallized with ddCTP
(PDB 2HVI).
The kinetics of the insertion of dATP, dCTP, dGTP, and dTTP opposite the 7CdG,
7Me7C

dG, and

7Me9C

dG catalyzed by Klenow Fragment (Kf) (exo-) of E. coli DNA pol I

were followed by PAGE. Initial rates were determined in reactions in which the extent of
reaction was less than 30% completion.79 The kinetic parameters for all reactions are
shown in Table 3.1.
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Replacing dG with the methyl did not significantly affect the binding of the DNA
to the polymerase and the Km’s of dCTP incorporation opposite all three templates were
similar. However, they were much higher than a typical Km of dCTP incorporation
opposite dG (1-10 nM).80 We have observed the next higher Km of dTTP incorporation
opposite all three templates, which may simply occur as a consequence of the geometric
constraints imposed by the tight binding pocket in a high-fidelity polymerase. dCTP
incorporation with

7C

dG,

7Me7C

dG and

7Me9C

dG significantly

decreases the binding

efficiency (90-900 fold) compared to dG. Because the only similarity between
7Me7C

dG, and

7Me9C

7C

dG,

dG that differs from dG is their nonexistent hydrogen bond-accepting

ability at N7, these results suggest that there may be an important major groove hydrogen
bond to the N7 of dG during dCTP incorporation. The difference in Km indicates that the
N7-position of guanine may be important for efficient dNTP binding. This result is
consistent with the crystal structure of Kf (exo-)/duplex DNA cocrystallized with ddCTP,
which shows a direct hydrogen bond between a water molecule and the N7 of dG
opposite the ddCTP.85 The same water molecule is also hydrogen-bonded to the amide
backbone of the protein. Thus, the loss the N7 lone pair disrupts the normal hydration in
the polymerase binding pocket, which may be crucial in the conformational change
certainly affects the binding of the DNA and the dNTP. Furthermore, dCTP was
incorporation opposite 7CdG, 7Me7CdG and 7Me9CdG with 2, 5 and 8-fold (Table 3.1) lower
kcat than opposite dG, which indicates that the loss of the N7 lone pair slowed down the
enzyme turnover slightly, whereas the size of the methyl group further amplified this
effect. The catalytic efficiencies for Kf (exo-) incorporating the correct dCTP opposite
7C

dG,

7Me7C

dG and

7Me9C

dG were reduced, with the kcat/Km values being 150, 68, and
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55(%.μM-1 sec-1), compared to the order of 104 (%.μM-1 sec-1) for unmodified dG
template. Thus, the methylgroup in the

7Me7C

dG and

7Me9C

dG confers a reduction in

efficiency for dCTP insertion by approximately 2 and 3-fold, respectively. The major
contributor to the reduction of catalytic efficiency is the weak binding resulting from the
loss of the N7 lone pair. Overall, this result suggested that substitution of dG with the
methyl group significantly slowed down polymerase replication; however, this catalytic
efficiency reduction seems unlikely to induce the recruitment of low-fidelity polymerases
in cells. The misinsertion frequencies (fmis) for dATP and dTTP opposite all three
templates were similar. However, The misinsertion frequency for dGTP opposite 7Me9CdG
was only slightly faster than those opposite

7Me7C

dG and

7C

dG. Overall, these three

synthetic bases can be considered nonmutagenic for misinsertion events, because the
misinsertion frequencies are still considered low compared to other known mutagenic
DNA lesions. This result is consistent with other studies that support 7-methylguanine
being non-mutagenic.
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Table 3.1 Steady-State Kinetics of dNTP Incorporation Opposite
7Me9C

7c

dG,

7Me7C

dG, and

dG by Kf (Exo-)

kcat/Km
(%.μM-1 sec-1)

fmis

294 ± 2.1
1.152 ± 0.186 170 ± 10
308.1 ± 80.5 99 ± 13

150
0.32

1
2.1 x 10-3

dGTP

87.17 ± 15.71 3.7 ± 0.2

0.042

3.0 x 10-4

dG

dTTP

40.27 ± 14.79 8.4 ± 0.8

0.21

1.4 x 10-3

7Me9C

dG

dCTP

1.180 ± 0.427 65 ± 8
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1

7Me9C

dG

dATP

196.9 ± 120.9 47 ± 10

0.24

4.3 x 10-3

7Me9C

dG

dGTP

74.87 ± 26.58 10 ± 1

0.14

2.5 x 10-3

7Me9C

dG

dTTP

46.05 ± 25.62 6.4 ± 0.9

0.14

2.5 x 10-3

7Me7C

dG

dCTP

0.562 ± 0.129 38 ± 2

68

1

7Me7C

dG

dATP

64.85 ± 30.78 9.5 ± 0.8

0.15

2.2 x 10-3

7Me7C

dG

dGTP

56.89 ± 19.54 2.6 ± 0.2

0.046

6.6 x 10-4

7Me7C

dG

dTTP

49.59 ± 10.57 7.2 ± 0.3

0.15

2.2 x 10-3

Template

dNTP

Km (μM)

dG
7C
dG
7C
dG

dCTP
dCTP
dATP

7C

dG

7C

kcat (%.sec-1)

3.4 Conclusion
For the first time, the influence of the methyl group of 7Me9CdG on polymerase action was
investigated by using chemically stable analogues. We found two important results. First,
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the Km of dCTP binding observed for all three templates were comparable (Table 3.1),
but much higher than the typical dG template (in the low nM range). An apparent
explanation is the loss of the metal-binding or hydration site provided by the N7 lone
pair. This loss might have caused distorted structure of the polymerase-template-primerdNTP quaternary complex. The second important result is that the kcat of dNTP
incorporation opposite
7Me9C

7C

dG is similar to dG, but significantly higher than

7Me7C

dG and

dG. This demonstrated that methyl group slowed down the turnover of the enzyme

although it was originally expected to play minor roles in affecting polymerase actions.
The fmis of the three templates were similar. They were about 2 orders of magnitude
higher than a typical dG template, but still considered low compared to other DNA
lesions. The methyl group itself does not cause significant misincorporation in highfidelity polymerases. It will also be important to expand these studies to additional
polymerases, including Dpo4 a (low fidelity Y-family polymerase).

CHAPTER 4
STABILITIES OF THE GLYCOSIDIC BONDS OF N7-METHYL-9-DEAZA-DGAND 7-METHYL-7-DEAZA-DG IN THE PRESENCE OF BASE EXCISION
REPAIR (BER) ENZYMES

4.1 Background Information
Cellular DNA is susceptible to chemical modifications when exposed to a wide spectrum
of exogenous and endogenous DNA damaging agents. These agents can lead to a wide
variety of nucleobase modifications that can occur by oxidation or alkylation. Persistence
of some of these DNA lesions can be mutagenic and/or cytotoxic. Genotoxicity and
cytotoxicity cause altered gene expression and cellular apoptosis, leading to aging,
cancer, and various neurological disorders. To combat the deleterious effects of DNA
lesions, cells have a variety of DNA repair pathways responsible for restoring damaged
DNA to its canonical form. Therefore studies of the mutagenicity of DNA lesions in vivo
have to be conducted on the basis of understanding what repair systems might have been
involved in attenuate the influence of the damage. On the other hand, unsuccessful repair
results in missing base information or DNA strand breaks, which leads to the formation
of secondary lesions. In this chapter, we have examined the base excision repair (BER)
pathway to confirm the stability of our modified nucleotide

7Me9C

dG. The base excision

repair pathway is a highly regulated network. The following are types of damages
repaired by BER pathway: alkylated bases, oxidized bases, deaminated bases, bases with
open rings, and AP sites.1 Incorporation of correct base in the BER pathway is essential
for the preservation chromosomal stability by protecting the cells from DNA strand
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breaks. The first enzyme to initiate the repair pathway is the DNA glycosylase, which is
responsible for the excision of the damaged base. There are two kinds of DNA
glycosylases; the monofunctional (MF) and the bifunctional (BF) DNA glycosylases. The
MF glycosylases only have the glycosylase activity that enables them to excise the
damaged base. They are hydrolase enzymes that simply use a water molecule to attack
the anomeric carbon of the damaged nucleotide. The resulting abasic site can be
efficiently excised in the base replacement segment of BER (Figure 4.1). The resulting
single-stranded and nicked AP sites are processed by AP endonuclease 1 (APE1), which
hydrolyzes the phosphodiester bond 5′ to the AP site. This generates a 3′ hydroxyl
substrate for replacement synthesis by DNA polymerase β, followed by sealing of the
resulting nick by DNA ligase complete the repair process. BF glycosylases differ from
their MF counterparts by their using an active site amine nucleophile rather than water
(Figure 4.1). This amine nucleophile also serves as a Schiff base electron sink to facilitate
subsequent β elimination. β-Elimination of an AP site by a glycosylase-lyase yields a 3'
α,β-unsaturated aldehyde adjacent to a 5' phosphate, which differs from the AP
endonuclease cleavage product.86 Some glycosylase-lyases can further perform δelimination, which converts the 3' aldehyde to a 3' phosphate. In addition, the BF DNA
glycosylases possess the AP lyase activity, and thus they are capable of cutting the
phosphodiester bond of the DNA, which creates the single strand break without the need
for the AP endonuclease activity.
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Figure 4.1 Two pathways for base excision repair of damaged bases in human DNA.87
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In the BER pathway, the N-glycosyl bond of the damaged base is cleaved by a
specific DNA glycosylase, releasing the damaged base. A wide variety of glycosylases
have evolved to recognize different damaged bases and can be grouped into the different
categories based on their substrates. To fulfill our motive to examine the stability of the
glycosidic bonds of

7Me9C

dG and

7Me7C

dG against the actions of DNA glycosylase, we

have used formamidopyrimidine DNA glycosylase (Fpg) and human alkyladenine DNA
glycosylase (hAAG) because
substrate of hAAG.81,
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7C

dG is a known substrate of Fpg and

7Me

dG is a known

hAAG catalyzes the hydrolysis of the N-glycosidic bond to

release the damaged base via MF repair pathway and generate AP site, whereas Fpg is a
BF DNA glycosylase (N-glycosylase and AP-lyase). The N-glycosylase activity releases
damaged purines from double stranded DNA, generating AP site. The AP-lyase activity
cleaves both 3´ and 5´ to the AP site thereby removing the AP site and leaving a onebase gap.

4.2 Experimental
5’-FAM labeled duplex DNAs (50 µM for each strand) were hybridized in 10 mM TrisHCl (pH 7.5) and 100 mM NaCl. A solution containing the DNA duplex (10 µM), 1
mg/mL BSA, 1 mM bis-tris-propane-HCl (pH 7.0), 1 mM MgCl2, 1 μM DTT, and the
enzyme (8 units) in a total volume of 10 μL was incubated at 37 ºC for 2 hours. For the
Fpg reaction, 10 μL of 90% formamide loading buffer was added to stop the reaction. For
the hAAG reactions, 1 μL of 3 M NaOH was added and the reaction was incubated for
another 15 min before neutralized with acetic acid. Then 10 μL of 90% formamide
loading buffer was added. Both reactions were heated at 90 ºC for 10 minutes before
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cooled on ice. The samples were analyzed by 20% denaturing PAGE. The gel was
visualized using AlphaImager® EP. The intensities of the bands were quantified using
Alphaview 3.0.

4.3 Results and Discussion of Glycosylase Assays
The stability of the glycosidic bonds of

7Me9C

dG and

7Me7C

dG against the actions of Fpg

and hAAG was studied. 5’-FAM-labeled duplex DNAs containing
(22), and

7Me7C

7C

dG (21),

7Me9C

dG

dG (23) were incubated with 1.67 μM (8 units in 10 μL) Fpg for 2 hours

(Figure 4.2a). Faster moving bands in the gel corresponded to the cleaved single-stranded
DNA generated via the AP lyase reactions and the deglycosylasation reactions catalyzed
by Fpg. Quantification of the bands showed that Fpg cleaved over 95% of the duplex
containing 7CdG while we observed 10% cleavage of the duplex containing 7Me7CdG. The
kcat of the cleavage of 7-deazaguanine is estimated to be 0.005 min-1, based on the fact
that the duplex DNA concentration (10 μM) used in this study was much higher than the
typical Km of an Fpg substrate. The duplex containing

7Me9C

dG was stable and remained

intact after 2 hours of incubation.
The same experiment was repeated for duplex DNAs containing 2’-deoxyinosine
(dI, 20),

7Me9C

dG (21), and

7Me7C

dG (22) with 67 nM (8 units in 10 μL) of hAAG for 2

hours (Figure 4.2b). hAAG does not have the AP lyase activity and thus the reaction was
further incubated with 0.3 M NaOH for 15 min to facilitate the cleavage of the AP site.
The base treatment was expected to generate a β-elimination product as well as a δelimination product. The total amount of cleavage of the duplex containing the dI:dC
base pair (20) was 59% and we have also observed weak cleaved bands (<3% in total) in
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lanes 11 and 12. To confirm that these bands were in fact caused by NaOH, we extended
the incubation time of 23 solely with NaOH to 18 h. We have observed that the percent
cleavage was increased to 55%. To further confirm the hAAG action in lane 12, we
extended the incubation time of 23 with hAAG to 18 hours and doubled the amount of
enzyme while maintaining the NaOH incubation time of 15 min. We have observed only
weak cleaved bands (Figure 4.3). Surprisingly,

7Me9C

dG did not show any sign of

cleavage, whether with NaOH alone or with hAAG followed by NaOH treatment. These
results demonstrated that 7Me9CdG was remained intact in the presence of hAAG whereas
hAAG is likely to cut

7Me7C

dG due to the broad substrate specificity (see later

discussions) would be at very low rate.
As a DNA glycosylase with broad substrate specificity, Fpg was previously
reported to remove N7-methyl-8-oxoguanine with much lower activity compared to the
removal of 8-oxoguanine (OG).5 The OG result in fact can help to explain that Fpg also
removed

7Me7C

dG but with much lower activity than

7C

dG. The hydrogen bond between

the backbone oxygen of a serine residue and the N7H of OG is responsible for the
selectivity of Fpg for OG over undamaged guanine.88 A similar CH-N hydrogen bond can
possibly form between the serine residue and the C7-H of 7CdG and when a methyl group
is added to the N7 position of OG or the C7 position of
severely affected.

7C

dG, the enzyme activity is
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5’- ATG GAG AGA AGG CAG GAT GCT ATC G-3’
3’- TAC CTC TCT TCC XTC CTA CGA ATG C-FAM-5’
Substrate 20, X= dI
21, X= 7CdG
22, X = 7Me9CdG
23, X = 7Me7CdG

Figure 4.2 PAGE analysis of cleavage of duplex DNA containing damaged Nucleobases
or Nucleobase Analogues. (a) Incubation with Fpg. Lane 1 and 2, substrate 21; lane 3
and 4, substrate 22; lane 5 and 6, substrate 23. Conditions of lane 1, 3, and 5: 10 µM
duplex, 1 mg/mL BSA, 1 mM bis-tris-propane-HCl (pH 7), 1 mM MgCl2, 1 μM DTT,
37C, 2 h; Conditions of lane 2, 4, and 6: same as lane 1, 3, and 5 except that Fpg (1.67
μM) was added. (b) Incubation with hAAG. Lane 7 and 8, substrate 20; lane 9 and 10,
substrate 22; lane 11 and 12, substrate 23. Conditions of lane 7, 9, and 11: 10 µM
duplex, 1 mg/mL BSA, 2 mM tris-HCl (pH 8.8), 1 mM (NH4)2SO4, 1 mM KCl, 200 μM
MgSO4, 37C, 2h, then 0.3 M NaOH, 37C, 15 min. Conditions of lane 8, 10, and 12:
same as lane 7, 9, and 11 except that hAAG (62 nM) was added.

Human AAG, excises a variety of substrates including alkylated purines and
hypoxanthine (Hx), the deamination product of adenine. hAAG also act on undamaged
purines but the activities of hAAG on dI and alkylated purine nucleosides are
significantly higher.89 In our experiment, we extended the reaction time for

7Me7C

dG to

18h and doubled the enzyme concentration. However, the results showed no obvious
cleavage other than the cleavage caused by NaOH.
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1

2

Figure 4.3 Incubation of duplex DNA 23 with NaOH. Conditions of lane 1, 2: 10 µM
duplex. Lane 1, in 0.3 M NaOH, 37C, 18 h. Lane 2, in 124 nM hAAG, 1 mg/mL BSA,
2 mM tris-HCl (pH 8.8), 1 mM (NH4)2SO4, 1 mM KCl, and 200 μM MgSO4, 37C, 18h,
followed by 0.3 M NaOH, 37C, 15 min.

hAAG may still cut

7Me7C

G at an extremely slow rate, which is similar to the

cleavage of undamaged purines. Although, the exact kcat cannot be measured under our
experiment conditions, the value must be lower than 3 x 10-4 min-1 if the amount of
cleavage after 18 h is considered less than 0.5%. This slow rate of cleavage should not
affect normal cellular studies.

4.4 BER Repair Inhibition Assay for Inosine in the Presence of 7Me9CdG
7Me9C

dG was stable against both enzymes, which opens up the possibilities that it can be

an inhibitor of BER enzymes. Since many anticancer drugs act by damaging DNA,
thereby arresting cells in the act of DNA replication. Thus, in this context, DNA repair is
undesirable and drugs that block repair of drug-induced lesions may synergistically
enhance the chemotherapeutic effect of some anticancer drugs. In this kind of therapy, an
artificial nucleotide within a duplex DNA strand that binds to BER enzymes but is not
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cleaved by them may serve as an inhibitor. By keeping this in our mind, we have
investigated the role of

7Me9C

dG as an inhibitor for hAAG. The hAAG assay for dI

cleavage was repeated in the presence of 22 in various concentrations (1-5 µM) to check
the inhibition effect of

7Me9C

dG. Percent inhibition of the enzyme activity was plotted

against the inhibitor concentrations. The result showed only a small effect of inhibition,
around 75% inhibition was observed at 5 μM of 22 (Figure 4.4). The inhibition constant
(Ki) was estimated to be around 75 nM based on the reported Km on a dI substrate.82,89

Figure 4.4 Inhibition of hAAG on a dI Substrate by duplex DNA containing

7Me9C

dG.

The experiments were performed in triplicates.

4.5 Conclusion
We have examined the stability of 7Me9CdG and 7Me7CdG in the presence of BER enzymes
Fpg and hAAG. A difficulty to study the biological effects of N7-methyl-dG adducts in
cells is due to their low stabilities. In contrast to the in vitro conditions where N7-methyldG can survive through a reasonable amount of time at ambient temperature and pH
conditions, cells contain a variety of BER enzymes that could potentially remove some of
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the N7-methylated bases quickly. The advantage of using a stable analogue of N7methyl-dG is not only to generate a single adduct through oligonucleotide synthesis, but
ensure that the chemical structure of interest remains intact if additional studies are to be
carried out in cells. Our studies showed that the glycosydic bond of 7Me7CdG 7 was cut by
Fpg at the kcat of 0.005 min-1. Although it is much lower than the values for OG (4.0 min1

) and

7C

dG (3.2 min-1), the cleavage will be significant if a study is to be carried out in

cells and last 1-2 days. 7-Me-7-deaza-dG was stable in the presence of hAAG for at least
18 h. Obviously, the reaction catalyzed by hAAG is slow, it is prudent to avoid the
structure of

7Me7C

dG if cellular studies are necessary. In contrast, its analogue

7Me9C

dG

was stable against both enzymes. Therefore, 7Me9CdG is a more versatile analogue of N7Me-dG than

7Me9C

dG, especially when in vivo study is needed. Inhibition studies of

hAAG on a dI substrate in the presence of duplex DNA containing 7Me9CdG demonstrated
that hAAG binds the inhibitor with a similar affinity to its substrate. This study has
generated a hypothesis that can guide future experimental and theoretical studies directed
to increase current knowledge of the mechanism of inhibition.

CHAPTER 5
DESIGN AND SYNTHESIS OF DNA METHYL TRANSFERASE INHIBITORS

5.1 Introduction
5.1.1 DNA Methylation
DNA methylation is a crucial biochemical reaction responsible for epigenetic regulation,
which greatly influences gene activation, chromatin stability, and so on.

Figure 5.1 Methylation of cytosine catalyzed by DNMTs.
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In mammals, normal DNA methylation is controlled by DNA methyltransferase
(DNMT), an enzyme that catalyzes the transfer of a methyl group from S-adenosyl-lmethionine (SAM) to the C5-postion of cytosine (Figure 5.1). SAM is a common
cofactor in cells. The methyl group attached to the cationic sulfur atom in SAM is
chemically reactive. This allows donation of this active methyl group from the sulfur
center to a specific position in a variety of substrates, e.g., DNA, RNA, proteins, and
secondary

metabolites

catalyzed

by

methyltransferases

(MTs).

More

than

40 metabolic reactions share this mechanism, and the product is S-adenosyl
homocysteine (SAH) (Figure 5.1), which is an inhibitor of the most methylases.

5.1.2 The Catalytic Mechanism of DNA Methylation
The catalytic mechanism of DNA cytosine-C5 methylation90 is shown as Figure 5.2.
DNMT forms a complex with DNA, and the cytosine to be methylated flips out from the
DNA. The thiol group of a cysteine residue in the active site of DNMTs serves as a
nucleophile that attacks the 6-position of the target cytosine to generate a covalent
intermediate. The 5-position of the cytosine is activated and conducts a nucleophilic
attack on the SAM to form the 5-methyl covalent adduct and SAH. The attack on the 6position is assisted by a transient protonation of the cytosine ring at the endocyclic
nitrogen atom N3. The proton is provided by a nearby a glutamic acid residue. The same
Glu residue is also in contact with the exocyclic N4 amino group. The extremely electron
negative O-2 may also be stabilized by an arginine residue. Following the methyl
transfer, the deprotonation at the 5-position generates elimination products: the
methylated cytosine and the free cysteine of the enzyme. If this C5 proton is absent,
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elimination does not occur and the enzyme becomes permanently bound to DNA. That is
how DNA methyltransferases are inhibited by many suicide inhibitors.

Figure 5.2 The proposed mechanism of DNA cytosine-C5 methylation.

5.1.3 Biological Importance of DNA Methylatransferase (DNMT)
All the known DNA methyltransferases use SAM as the methyl donor. There are four
different DNMTs known in mammals: DNMT1, DNMT3a, DNMT3b and DNMT3L.
DNMT1 (DNA cytosine-5-methyltransferase1) is responsible for the maintenance of
methylated DNA by copying DNA methylation patterns from the parental strand to the
newly synthesized daughter strand during the DNA replication process. DNMT1 is
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ubiquitous; it is highly expressed in fetal tissues, heart, kidney, placenta, peripheral blood
mononuclear cells, and less expressed in spleen, lung, brain, small intestine, colon, liver,
and skeletal muscle.91, 92 Differently, de novo methyltransferase DNMT3A is only present
in low amounts in somatic cells and shows no preference for hemi- or unmethylated
DNA.93 It is widely accepted that DNMTs play a causal role in cancer formation through
their DNA methylation activity on tumor suppressor genes, which makes them suitable
candidates for anticancer targets.94

5.2 Developed DNMT Inhibitors
DNMT inhibitors (DNMTi) can be classified into two broad categories. One category
includes nucleosides inhibitors, which are incorporated into DNA and act as suicide
inhibitors via a covalent adduct formation. The second category is the non-nucleoside
inhibitors.95 To date, only two nucleoside analogs, 5-azacytidine (Vidaza) and 5-aza-2’deoxycytidine (also known as Decitabine, Dacogen), have been used clinically. These
drugs, after incorporation into DNA, cause covalent trapping and subsequent depletion of
DNMTs. Azacitidine and Decitabine are approved by the FDA for the treatment of
myelodysplastic syndrome.96 These 5-azanucleoside analogues can be incorporated into
DNA to replace cytosine. The absence of a hydrogen atom at the C5 position hinders
DNMT release by β–elimination, with the consequence of DNMT trapping and
degradation (Figure 5.4).

Because of the nitrogen substituted base forms a stable

covalent complex with DNMT, the cytotoxicity associated with aza-nuclosides increased
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Figure 5.3 Nucleoside DNMTi.

the demand for more effective and selective DNMTi. Zebularine (Figure 5.3) is a novel
DNMT inhibiting drug which offers much promise due to low toxicity, stability and
effective bioavailability when administered orally. It also has high selectivity for tumor
cells. The downfall of this drug has been the requirement for high doses (1 g/kg in
mouse) which may pose problems in clinical trials.97
To avoid the toxicity and stability problems associated with nucleoside DNMTi,
efforts have focused on the development of non-nucleoside reversible inhibitors.
Generally, they inhibit DNA methylation by binding directly to DNMTs without
incorporation into DNA. Some of the reversible DNMTi’s (Figure 5.5a) are approved
drugs for other indications, e.g., the anti-hypertensive drug Hydralazine, the local
anesthetic Procaine, the anti-arrhythmic drug Procainamide,98 and the methylene
disalicylic acid NSC1477899 (Figure 5.5b). Some DNMT inhibitors have been identified
by docking-based virtual screening. Examples include the L-tryptophan derivative
RG108 (Figure 5.5b), RG108 (NSC401077) was first characterized by Brueckner et al. 100
in 2005 and was conceived to interact with the catalytic domain of DNMT1.101 This
compound inhibits DNMT in human cancer cells. DNMT inhibitor MG98 (Structure has
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not been disclosed yet) can safely and effectively lead to reactivation of methylation
silence tumor suppressor genes. This has been shown in patients with RCC, a disease
associated with hypermethylation and silencing of cell growth control and tumor
suppressor genes.102 MG98 seemed promising and was used in a Phase I study in solid
tumors.103 Because of current preclinical and clinical evidence, further phase II
development of MG98 would be of interest. Recently, a non-nucleoside inhibitor, SGI1027, (Figure 5.5c) and its analogues were developed which showed high potency in the
anticancer activities.104, 105

Figure 5.4 The mechanism of 5-azanucleoside analogues induced degradation of
DNMTs.

Unlike genetic changes, epigenetic changes can be modified by the environment,
diet, or pharmacological intervention. There are many bioactive dietary compounds that
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can modulate the DNMT enzyme activities and thus promoter methylation pattern of
genes in cancer. Apigenin in Parsley (Petroselinum), curcumin (1,7-bis (4-hydroxy- 3methoxyphenyl)-1,6-heptadiene-3,5-dione) in turmeric (Curcuma longa), EGCG in green
tea (Camellia sinensis), genistein in soybean (Glycine max), resveratrol (3,40,5trihydroxytrans- stilbene) in red grapes (Vitis vinifera), sulforaphane (SFN) in
cruciferous vegetables (Brassicacaae), and the caffeic acid and chlorogenic acid as
coffee polyphenols were reported to inhibit DNMT enzyme activity in various cancer
models.106, 107
SAH can bind to DNMTs and inhibit their catalytic reaction and has an important
role in the regulation of biological DNA methylation. SAH analogs presumably binding
in the co-factor binding pocket have also been reported as selective inhibitors against
DNMT1 over DNMT3b2 by using rational design approach.108 According to previous
data (Figure 5.5 d (a)), replacement of the homocysteine side chain by the five membered
(2S,4S)-4-mercaptopyrrolidine-2-carboxylic acid was a good replacement, while the
corresponding six-membered counterpart was less active. It was also found that deletion
of the carboxylic group (Figure 5.5 d (d)) eliminating the zwitter-ionic character was less
active against enzymes. In addition, another SAH analogue (Figure 5.5e), which contains
a shorter carboxyl side chain, was reported109 to be a strong inhibitor for DNMTs,
although a natural compound Sinefungin(figure 5.5f) is more potent.110
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Figure 5.5 Chemical structures of non nucleoside DNMT inhibitors and other selected
compounds with proposed demethylating activity. (a) Drugs used for other indications,
(b) Compounds identified using virtual screening, (c) SGI-1027 and its analogue105 (d)
and (e) SAH analogs (f) Sinefungin.104
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5.3 Crystal Structure Study and Design Concept for DNMTi
SAH is a known strong inhibitor of DNA methyltransferases at the SAM binding site,
although the biological roles of SAH on the inhibition of DNMTs are not completely
understood. Furthermore, SAH-binding proteins are widely found in cells and it is
unlikely to use SAH to selectively inhibit DNMTs. The ideal inhibition should fill the
following

requirements.

First,

they

can

specifically

inhibit

cytosine

DNA

methyltransferases vs. other methyltransferases, and second, as mentioned earlier, they
should bind DNMTs reversibly. The crystallographic structure of human DNMT1 is a
very important tool to guide the design. There is more than one binding site within
DNMT1. The one for SAM and the one for the extra helical cytosine of the duplex DNA
are close to each other. It can be expected that an SAH analogue that occupies both
pockets at the same time would selectively bind DNMTs. However, there is a concern
whether this SAH analogue would bind differently in the absence of the DNA, as a study
on a prokaryotic DNMT suggested that binding of SAM occurred after DNA binding,
therefore it is likely that the SAM binding pocket is shaped through DNA binding. A
superposition study of a bound SAH in DNA-free mDNMT1 and the productive covalent
mDNMT1-DNA complex was performed by Wu111 to evaluate the significance of the
change. The results showed that SAH undergoes a slight positional shift from the DNAfree state to its productive covalent complex with DNA. Although the overall structural
change is so small that the SAH analogue would bind the protein in its active
conformation in the absence of the DNA shown as Figure 5.6.112
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Figure 5.6 Interactions between SAH mDNMT1-DNA complex. Left: Interactions
between SAH and binding pocket residues in free mDNMT1. Right: Bound SAH in the
productive covalent mDNMT1-DNA complex is stabilized. Hydrogen bonds: black
dashed lines; hydrophobic interactions: green dashed lines. 112

The crystal structure of SAH and human DNMT1-DNA complex (figure 5.7)
provided additional detailed information on the relative geometric locations of these two
binding sites. The flipped out cytosine adopts an extra helical position to insert into a
cytosine binding site that is in close proximity to the sulfur of SAH (Figure 5.7). The
distance between the carbon at 5 position of cytosine and the sulfur atom of SAH is 4.5
Å. The flipped-out cytosine was stabilized by surrounding residues in the active site of
the enzyme. (Figure 5.8) The carbonyl of the cytosine forms two hydrogen bonds with
Arg 1313 and Arg 1315, and the 3-nitrogen forms a hydrogen bond with Glu 1269. The
4-amino group forms a hydrogen bond with the backbone of Pro 1227. This result
indicates that the carbonyl group, the 3-position nitrogen and the 4-position amino group
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of cytosine may play vital roles in binding. The 3-nitrogen may be less important when
Glu1269 is deprotonated.

Figure 5.7 The crystal structure of SAH and human DNMT1-DNA complex (PDB:
4DA4). SAH1701 in chain A, Cytosine4918 in chain D, and parts of the DNA sequences
in chain D were selected and shown only.111

Figure 5.8 The flipped-out cytosine is stabilized by surrounding residues in the active
site of the enzyme.112
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A transition state analogue was designed to occupy the SAM binding site and the
cytosine binding site simultaneously. It was decided that part of the SAM core structure
was to be kept and part to be deleted. First, adenosine and the long chain should be kept.
As Figure 5.6 shows, SAH can form several hydrogen bonds with the amino acid residues
at the binding site of DNMT1, such as Glu 1171, Met 1172, Leu 1154, Val 1582, Gly
1153. Therefore, to maintain these interactions between DNMT1 and SAM analogues,
the adenosine and carboxyl group with the long chain should be kept. Second, to be a
selective inhibitor, extra binding interactions other than the ones involving SAH are
required. The process of DNA cytosine methylation involves the addition of a methyl
group to cytosine at the C5 position. Therefore, introducing a cytosine to the SAM
analogue may enhance binding by taking advantages of the interactions between cytosine
and cytosine-binding side chains. To simplify the synthesis, it was decided to use other
functionalized aromatic rings (benzene or heterocyclic rings) to replace cytosine. Third,
the sulfur atom with positive charge can be changed to a nitrogen atom, which is
expected to be protonated under physiological conditions. Fourth, the α-amino group of
SAM can be removed because it is not involved in any interaction with the protein, and it
may affect the protonation state of the adjacent tertiary amine.

Figure 5.9 Design of a transition state inhibitor of DNMT.
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In summary, the design of SAM analogues was inspired by the catalytic
mechanism of DNMT and the study of the crystal structure of DNMT/DNA/SAH
complex. The distance between the branching nitrogen and the aromatic ring is set to be 2
C-C bond-long to reflect the distance during the methyl transfer in the catalytic
mechanism. A series of compounds were designed that contained different aromatic
derivatives. These derivatives were expected to interact with the amino acid side chains
mimicking the flipped cytosine in the catalytic mechanism. Among these compounds, 24
was previously prepared by Wu.111 The preparation of 25 and 26 is described below.

5.4 Synthesis of DNMT Inhibitors
5.4.1 Retrosynthetic Analysis

Scheme 5.1 Retrosynthetic Analysis of Target Compounds.
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Compound 24-26 can be generated from three parts according to our
retrosynthetic analysis (Scheme 5.1): the phenylacetaldehydes (33, 34), methyl 4oxobutanoate, and 5’-amine-modified adenosine 31. The three parts will be joined
together by two successive reductive amination reactions.

Scheme 5.2 General Synthesis Route. (a) NaBH3CN, AcOH, (b) p-TsOH.H2O (2equiv.),
MeOH, (c) KOH.

The general synthetic strategy after the first reductive amination reaction is shown
in scheme 5.2. In the case of the synthesis of 25, the O-Bn group was removed by
hydrogenolysis. The acetonide protection on the 2ʹ- and 3ʹ hydroxyl groups was removed
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via acid-catalysis methanolysis. The methyl esters were hydrolyzed under strong alkaline
conditions.

5.4.2 Synthesis of the Common Precursor 31
The synthesis started from commercially available adenosine. The 2ʹ-and 3ʹ-hydroxyl
groups were protected using acetonide. The reaction initially finished in nearly 60%
yield. The reaction conditions included 11 mol equivalents of p-toluenesulfonic acid (pTsOH) and a large excess of acetone, which was both a reactant and a solvent. The
product was isolated by organic extraction. Several conditions have been examined to
improve the reaction yields. We changed the amount of p-TsOH to 4.3 mol equivalents
and decreased the solvent volume by 10 folds (Scheme 5.3). This change increased the
acid catalyst concentration although the total amount of catalyst became less. In addition,
extremely dry acetone was successfully prepared by fractional distillation over Drierite®.
Potassium carbonate pellets were added directly to the reaction mixture to neutralize pTsOH. This workup procedure avoided aqueous conditions which could convert some of
the product back to the starting material due to the slow neutralization process. The yield
was improved to 93% yield, higher than reported in most literatures.113,

114

After the

acetonide was installed, a leaving group was introduced by transforming the free 5ʹhydroxy group of the 2ʹ, 3ʹ-O-isopropylideneadenosine (27) into a mesylate ester (28)
using MsCl (Methanesulfonyl chloride) in the presence of triethylamine (TEA).
Increasing mol. equivalence of MsCl from 1.2 to 1.6 and lowering solvent volume by 9
fold improved product yield. Compound 28 was very unstable and it was initially directly
converted to an azide by adding sodium azide to the crude product in DMF without
further purification. Later we found that purification of compound 28 using oven-dried
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silica gel chromatography gave high recovery and the subsequent reaction with azide
could be completed in much improved yield. Reduction of compound 29 was achieved by
hydrogenolysis on Pd/C at 50 psi, which gave 5ʹ-aminoadenosine derivative 30

Scheme 5.3 Synthesis of Compound 31 (a) Acetone, p-TsOH, rt, 2 h, 93%. (b) CH2Cl2,
EtN3, MsCl, rt, 1.5 h, 89%. (c) NaN3, DMF, 70°C, 48 h, 60%. (d) H2, 10% Pd/C, MeOH,
50 psi, 16 h, 70%. (e) NaBH3CN, AcOH, methyl-4-oxobutanoate, rt, 1.5 h, 12%.
Reductive amination of compound 30 with methyl 4-oxobutanoate was hard to
control. As a result, disubstituted byproduct was formed: the mono- and di-substituted
products could not be completely separated (Scheme 5.4.). Reducing the amount of
methyl 4-oxobutanoate by 3 folds gave better selectivity, however, with a comprised low
yield. The desired product was obtained in pure form in 12% yield from the amine
(Scheme 5.1).
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Scheme 5.4 Reductive Amination of Compound 30.

5.4.3 Synthesis of 2-(o-Benzyloxy)phenylacetaldehyde (33)
The benzyl protected 2-(o-benzyloxy)phenylacetaldehyde can be synthesized from the
commercially available 2-(o-hydroxyphenyl)ethanol. First, the 2-hydroxyl group was
protected with a benzyl group (scheme 5.5) to prevent oxidation in next step. The next
step is the oxidation of (2-(o-benzyloxyphenyl)ethanol. IBX (2-iodoxybenzoic acid ) was
used to oxidize the starting material to generate the desired compound 33 in 33% yields
(Scheme 5.5).
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Scheme 5.5 Synthesis of 2-(o-Benzyloxy)phenylacetaldehyde (33) (a) K2CO3,BnBr,
DMF, 60°C, 16 h, 52%. (b) IBX, THF, 60°C, 16 h, 33%.

5.4.4 Synthesis of Compound 25
Compound 33 was reacted with 31 via reductive amination and the product 36 was
purified by column chromatography (Scheme 5.6). The product formation was confirmed
by Mass analysis (Figure 5.10a). The benzyl group was removed by hydrogenolysis. The
product was subjected to acid methanolysis to remove the acetonide (Scheme 5.7). The
product was used directly for next base hydrolysis reaction. After base hydrolysis, the
final compound 25 was obtained. The yield of compound 25 was too low for column
chromatography purification. Therefore, it was purified by HPLC and the collected
fractions were analyzed by Mass spectroscopy (Figure 5.10b).
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Scheme 5.6 Synthesis of Methyl Ester Compound 36.

Scheme 5.7 Synthesis of Compound 25. (a) H2, 10% Pd/C, MeOH, 50 psi, 4 h (b) 0.2M
HCl,MeOH:H2O (10:1),rt, 16 h(c) 0.4M KOH, MeOH:H2O (10:1),rt,16 h.
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Figure 5.10a Mass Spectra of Compound 36. (Bottom: ESI-MS (M+H+) for C33H40N6O6,
expected 617.3082, found (on top) 617.2929)
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Figure 5.10b Mass Spectra of Final Compound 25. Observed ESI-MS (M+H+)
475.3316(C22H31N6O6).

Figure 5.11 Cyclohexanone Derivative of Compound 25

However, the Mass spectrum of the expected fraction showed a molecular ion
with higher m/z than expected: ESI-MS (M+H+) for C22H29N6O6, expected 473.2065,
Observed

ESI-MS (M+H+) 475.3316(C22H31N6O6) (Figure 6.1b). One possible

explanation for this observation is that the phenol product was further reduced in the
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hydrogenolysis conditions and the cyclohexanone derivative of compound 25 was
generated (Figure 5.11).

5.4.5 Synthesis of 4-Nitrophenylacetaldehyde (34)
Compound 34 needs to be synthesized by oxidation from 4-nitrophenylethanol. PCC
oxidation was tried at the beginning. To our surprise, 1H NMR study of the product
showed that despite the presence of the aldehyde peak, the expected CH2 peak was
missing at around 3-4 ppm (Figure 5.12). The spectrum agreed with the formation of 4nitrobenzaldehyde (Scheme 5.8 (a)), which implied that this oxidation condition was too
strong. The C-C bond of the possibly formed 4-nitrophenylacetaldehyde was cleaved in
such conditions. Later, we decided to tried milder oxidation reaction. Neither Swern
oxidation nor TEMPO-NaClO oxidation gave the desired product. Therefore DMP was
selected as the oxidant.
We planned to use DMP (Dess–Martin periodinane) because DMP is mainly used
as an oxidant for complex, sensitive and multifunctional alcohols. According to reported
procedure, we synthesized DMP from IBX (2-iodoxybenzoic acid) and acetic
anhydride.54, 115 The product was directly precipitated from the reaction mixture when the
temperature was cooled to room temperature. The resulting white solid was not soluble in
methylene chloride, suggesting that DMP was not completely formed and the precipitate
contained a large amount of IBX. Reaction with this self-prepared DMP proceeded but
generated poor yields even with extended time. Later we used pure IBX to replace DMP
and increased the temperature for the reaction and obtained final compound 34 in 34%
yield (Scheme 5.8 (b)).116
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Scheme 5.8 Synthesis of Compound 4-Nitrophenylacetaldehyde (34).
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Figure 5.12 1H NMR Spectrum of 4-nitrobenzaldehyde.
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5.4.6 Synthesis of Compound 26
During the synthesis of 36, we found through NMR study that methyl 4-oxobutanoate
was oxidizing slowly in air, which could impact the yield and the purity of the reductive
amination product. Methyl 4-oxobutanoate is expensive and it is unlikely to purchase a
new batch for each reaction. Therefore we have decided to prepare the material in our
lab. Ethyl 4-bromobutyrate was identified as the commercial precursor to ethyl 4oxobutanoate. Several efforts were made to realize this transformation. The first attempt
was the direct oxidation of the alkyl bromide to generate the aliphatic aldehyde.
Oxidation of alkyl halides with pyridine N-oxide has been known as a unique method to
obtain carbonyl compounds.117 N-oxide is the oxidized product of a tertiary amine, which
finds wider application as an oxidants.118 It can be prepared using a variety of oxidants
including m-chloroperoxybenzoic acid (mCPBA) and hydrogen peroxide.
Accordingly,

4-dimethylaminopyridine

N-oxide

(DMAP

N-oxide)

was

synthesized using m-CPBA.119 IR spectrum showed complete conversion to DMAP NOxide. The resulting DMAP N-Oxide was used directly for the oxidation of ethyl 4bromobutyrate (Scheme 5.9 (a)). However, crude NMR of the reaction showed no peak at
around 9-10 ppm, indicating no aldehyde product was formed. It was also reported120 that
oxidation of primary, secondary, and tertiary amines with basic permanganate and rapid
isolation of the reaction products result in an advantageous method for degrading amines
to aldehydes and ketones. Accordantly, we tested the reaction using ethyl 4aminobutyrate hydrochloride as a staring material to synthesize ethyl 4-oxobutanoate
(Scheme 5.9 (b)).121 Unfortunately, this reaction did not afford the desired product either.
Finally, oxidation of ethyl 4-bromobutanoate was made successful by using commercial
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pyridine N-Oxide (Scheme 5.9 (c)). The reaction was completed in 16 h and purified by
column chromatography, giving ethyl 4-oxobutanoate in 9.6% yield. This low yield
became a problem for the next steps when the synthesis was scaled up.

Scheme 5.9 Synthesis of Ethyl 4-Oxobutanoate.

Compound 30 was reacted with ethyl 4-oxobutanoate via reductive amination
(Scheme 5.10). However, even with this freshly-made highly pure aldehyde, we still
could not improve the yield. This suggests that the selectivity of N-alkylation of primary
amine is inherently difficult to control. Later, we have changed our reaction route. Since
compound 34 was less costly than ethyl 4-oxobutanoate, we tried the first reductive
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amination with compound 34 and 30 in hope that the monoalkylated product can be
obtained in higher selectivity. Unfortunately, the improvement was minimal (Scheme
5.11).

Scheme 5.10 Modified Synthesis of Compound 31a (by reductive amination).
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Scheme 5.11 Reductive Amination of Compound 30 and Compound 34.

Discouraged by the failures to obtain pure compound 31 via reductive amination,
we decided to directly synthesize 31 with SN2 reaction of ethyl 4-bromobutyrate.
However, this N-alkylation reaction appears deceptively simple but it is often unselective
due to the concomitant overalkylations which give rise to mixtures of primary, secondary,
and tertiary amines, as well as quaternary ammonium salts. Although, by careful
adjustment of reaction parameters such as the relative proportions of the reactants,
reaction temperature, and the use of additives, one can tune conditions accordingly, so
that the secondary amine becomes predominant. The common protocol includes the most
conventional conditions utilize an alkali metal carbonate (e.g. K2CO3) in a polar aprotic
solvent (DMF,DMSO,or MeCN) at room temperature or under heating, depending on the
nature of the starting materials.121 It was also observed that the course of the alkylation
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was strongly dependent on the number of carbon atoms present in the alkyl bromide;
longer chain underwent alkylation more efficiently to afford monoalkylation product.
Conversely, use of smaller chain lengths(<5 carbons) reversed the selectivity, giving rise
to dialkylamines.121

Scheme 5.12 Synthesis of Compound 31a (by N-alkylation).
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Scheme 5.13 Synthesis of Compound 26 (a) NaBH(OAC)3,Methanol, rt, 1h, 16%. (b)
0.5M HCl, MeOH: H2O (1:0.2), rt, 16 h. (c) 0.1M KOH, MeOH: H2O (1:0.3), rt, 42 h,
72%.

To synthesize compound 31b, ethyl 4-bromobutyrate was added in portion and
DMF was added as co-solvent to increase the solubility of K2CO3. These efforts
contributed to the formation of desired product 31. (Scheme 5.12).122 The product was
purified by column chromatography in 25% yield. The second reductive amination was
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performed as shown as scheme 6.21, giving compound 38 in 13 % yield. After acid and
base hydrolysis, the final compound 26 was obtained (Scheme 5.13).

5.5 Materials and Methods

5.5.1 Organic Synthesis
All chemicals were purchased from Sigma-Aldrich or Fisher Scientific unless specified.
Acetone was dried over Drierite® and then distilled under Ar. CH2Cl2 and DMF were
distilled over CaH. NMR spectra were recorded on a 300 MHz Bruker spectrometer or
500 MHz Varian spectrometer. A liquid chromatography Model SIL-10 A (Shimadzu
Crop.) was used. A LC real time analysis computer integrator was used for retetion time
mesurements. The UV-Vis detector SPD-20A (Shimadzu Corp.) was used as follows
detector 1= 260 nm and detector 2= 260 nm. A C-18 reversed phase (7.8 X 150mm)
column filled with 10 µm (average particle size) was also used.

Compound 27: To a suspension of adenosine (2.0 g, 7.5 mmol) in dry acetone (20 mL)
was added 36.5 mmol of dry p-TsOH (6.3 g, 4.2 equiv.) in one portion. The mixture was
stirred under an atmosphere of Ar at room temperature for 2 h. The mixture was stirred
with 100 mL 0.5M K2CO3 solution for 10 min and then extracted with methylene
chloride till no spot from the organic extract can be observed on TLC. The organic layer
was dried over MgSO4 and then filtered. The solvent was evaporated. The product was
directly used for the next reaction without purification. The white solid was obtained
(2.14 g, 93%):1H NMR (300 MHz, CDCl3) δ ppm 1.39 (s, 3 H) 1.66 (s, 3 H) 3.97 (s, 1 H)
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4.57 (s, 1 H) 5.12 (s, 1 H) 5.19 (s, 1 H) 5.83 (s, 1 H) 5.91 (s, 1 H) 6.52 (s, 1 H) 7.99 (s, 1
H) 8.33 (s, 1 H).

Compond 28: A solution of 4.88 mmol of 2ʹ,3ʹ-O-isopropylideneadenosine (1.5 g) in 20
mL of dry dichloromethane was flushed with Ar before 1.71 mL of triethylamine (11.7
mmol, 2.4 equiv.) and 0.57 mL methanesulfonyl chloride (7.32 mmol, 1.5 equiv.) were
added.123 Solution was stirred at room temperature for 1.5 hr and then 20 mL of saturated
NaHCO3 solution was added. The layers were separated and the organic layer was
washed with 20 mL sat. solution of NaCl. The combined organic layers were dried over
MgSO4 and the solvent was evaporated. The crude product was purified by silica gel
chromatography (Ethyl acetate/ Hexane 9:1) to give the mesylate ester (1.8 g, 89 %) as
colourless foam. The product was directly used for the next reaction without NMR
identification.

Compound 29: A mixture of 28, (1.70 g, 40 mmol) and sodium azide (2.60 g, 0.04
mmol, 10 equiv.) was suspended in anhydrous DMF (18 ml). The reaction was heated at
70 °C for 48 hr.124 The mixture was filtered, and evaporated under reduced pressure.
DMF was removed in vacuo. The residue was purified by silica gel chromatography
(Ethyl acetate/Hexane 1:9). A Light yellow syrup (818 mg, 60%) was obtained. 1H NMR
(500 MHz, METHANOL-d4) δ ppm 1.33 - 1.41 (m, 3 H) 1.57 - 1.64 (m, 3 H) 3.67 - 3.82
(m, 2 H) 4.37 (br. s., 1 H) 5.04 (d, J=6 Hz, 1 H) 5.27 (br. s., 1 H) 6.09 - 6.18 (m, 1 H)
8.15 - 8.22 (m, 1 H) 8.29 - 8.35 (m, 1 H).
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Compound 30: Compound 3 (428 mg) was dissolved in 10 mL methanol; 21.4 mg of
10% Pd/C was added. The reaction mixture was placed under Ar and then under an
atmosphere of H2 at 50 psi and the reaction was stirred at r.t for 16 h. The mixture was
filtered, and evaporated under reduced pressure. The residue was purified by silica gel
chromatography (15% MeOH in DCM) Compound 30 (282 mg) was obtained in 70%
yield. 1H NMR (300 MHz, CD3OD) δ ppm 1.27 - 1.35 (m, 3 H) 1.49 - 1.57 (m, 3 H)
2.86 (d, J=6 Hz, 2 H) 4.14 - 4.21 (m, 1 H) 4.96 (d, J=9 Hz, 1 H) 5.38 - 5.45 (m, 1 H) 6.09
(1 H) 8.11 - 8.17 (m, 1 H) 8.22 (s, 1 H)

Compound 31: NaBH3CN 37 mg (0.58 mmol, 1 equiv.) and AcOH 91.7 μL were added
to a solution of 180 mg of compound 30 (0.58 mmol, 1 equiv.) and 18 μL of methyl 4oxobutanoate (0.18 mmol, 0.3 equiv.) in 1.5 mL MeOH. The reaction mixture was stirred
at room temperature for 1.5 h. After diluting the reaction with ethyl acetate, the organic
layer was washed with NaHCO3, dried over MgSO4, and then evaporated under reduced
pressure. The residue was purified by silica gel chromatography (dichloromethane/
methanol 50:3). Compound 5 (28 mg) was obtained in 12% yield. 1H NMR (300 MHz,
CD3OD) δ ppm 1.41 (s, 3 H) 1.58 - 1.64 (m, 3 H) 2.30 (td, J=7, 2 Hz, 2 H) 2.42 - 2.84
(m, 6 H) 3.65 (s, 3 H) 4.29 - 4.41 (m, 1 H) 5.03 (dd, J= 6, 3 Hz, 1 H) 5.54 (d, J=6, 2 Hz,
1 H) 6.20 (d, J=2 Hz, 1 H) 8.26 (s, 1 H) 8.29 (s, 1 H)

Ethyl 4-oxobutanoate: A mixture of 0.54 mL of ethyl 4-bromobutyrate, 800 mg of
pyridine oxide and 673 mg NaHCO3 in 10 mL of toluene was refluxed for 16 hours.
After return to ambient temperature, the reaction medium is diluted with 100 mL of EA
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and then wash with Brine. The crude product was dried on Na2SO4, evaporated under
reduced pressure and purified by silica gel chromatography. Compound Ethyl 4oxobutanoate (50 mg) was obtained in 9.6 % yield. 1H NMR (300 MHz, CDCl3) δ ppm
1.27 (s, 3 H) 2.63 (s, 2 H) 2.80 (s, 2 H) 4.14 (s, 3 H) 9.82 (s, 1 H)

Compound 31a(by reductive amination): NaBH3CN 12.56 mg (0.2 mmol, 1 equiv.)
and AcOH 13 μL were added to a solution of 60 mg of compound 4 (0.2 mmol, 1 equiv.)
and Ethyl-4-oxobutanoate (0.06 mmol, 0.3 equiv.) in 1.0 mL MeOH. The reaction
mixture was stirred at room temperature for 20 min. After diluting the reaction with ethyl
acetate and sat. NaHCO3 (aq.), the organic layer was washed with NaHCO3, dried over
MgSO4, and then evaporated under reduced pressure. The residue was purified by silica
gel chromatography (dichloromethane/methanol 50:6). Compound 31a (8.3 mg) was
obtained in 10% yield. 1H NMR (300 MHz, CDCl3) δ ppm 1.17 - 1.31 (m, 3 H) 1.38 (s,
3H) 1.62 (3 H) 2.11 (s, 1 H) 2.21 - 2.60 (m, 4 H) 2.98 - 3.54 (m, 3 H) 4.02 - 4.20 (m, 3 H)
5.10 (br. s., 1 H) 5.29 - 5.54 (m, 1 H) 6.02 - 6.27 (m, 2 H) 7.95 (br. s., 1 H) 8.26 - 8.39
(m, 1 H)

Compound 31a (by N-alkylation): To a solution of compound 30 in CH3CN: DMF
(80:1) was addded Ethyl 4-bromobutyrate (114 mg, 0.84 ml) and K2CO3 (100 mg). The
mixture was heated to 80°C 16 h. After cooling, the mixture was filtered. The filtrate was
concentrated and purified with column chromatography (DCM/ methanol 100:6) to yield
31b as a white foam (77 mg, 25%). 1H NMR (300 MHz, CDCl3) δ ppm 1.17 - 1.29 (m, 3
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H) 1.33 - 1.45 (m, 3 H) 1.62 (s, 3 H) 1.86 (t, J=7 Hz, 2 H) 2.28 - 2.43 (m, 2 H) 2.73 (d,
J=9 Hz, 1 H) 2.90 - 3.08 (m, 1 H) 4.03 - 4.17 (m, 2 H) 4.43 (d, J=2 Hz, 1 H) 5.10 (dd,
J=6, 3.03 Hz, 1 H) 5.44 (dd, J=6, 3.19 Hz, 1 H) 6.00 (d, J=3 Hz, 2 H) 7.93 (s, 1 H) 8.32
(s, 1 H)

Compound 33: To a suspension of compound 2-hydroxyphenethyl alcohol (220 mg, 1.6
mmol) in DMF (5 ml), K2CO3 (240 mg) was added. To this solution was added benzyl
bromide (220 µl) and the mixture was stirred at 60°C temperature for 16 h. The residue
was dissolved in ethyl acetate (100 mL); the solution was washed with H2O and brine,
dried over MgSO4, and concentrated. The crude product was purified by column
chromatography (1:19 Hexane: DCM) to yield (2-(o-benzyloxy) phenyl) ethanol (190
mg, 52%).
A solution of 2-(o-benzyloxy)phenylethanol (23 mg, 0.10 mmol) and IBX(42
mg, 0.15 mmol) was stirred at 60°C in THF (3 mL) for 16 h. The reaction was diluted
with diethyl ether (5 mL) and washed with sodium thiosulfate (5 mL) followed by
saturated sodium bicarbonate (5 mL). The aqueous layer was back-washed with diethyl
ether (10 mL). The organic layers were combined, washed with brine, and dried over
magnesium sulfate. The solvent was evaporated, and the crude was purified with column
chromatography (30:20 hexanes/DCM) to yield 7 (7.5 mg, 0.33 mmol, 33%). 1H NMR
(500 MHz, CDCl3) δ ppm 3.72 (2 H) 5.11 (s, 2 H) 6.99 (d, J=7 Hz, 2 H) 7.16 - 7.46 (m, 7
H) 9.74 (d, J=1 Hz, 1 H).
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Compound 34: To a stirred solution of 4-nitrophenyl alcohol (0.36 mmol) in acetonitrile
(3 mL) was added at once 2-iodoxybenzoic acid (IBX, 0.36 mmol). The mixture was
heated at 80 °C for 2 h and then cooled to rt. The mixture was then filtered through
Celite® and the solvent was evaporated, giving the expected crude material as a yellow
oil. The crude was purified with column chromatography (90:10 hexanes: ethyl acetate)
to yield 34 (20 mg, 34%). 1H NMR (300 MHz, CDCl3) δ ppm 3.88 (d, J=1 Hz, 2 H) 7.40
(d, J=8 Hz, 2 H) 8.20 - 8.28 (m, 2 H) 9.83 (t, J=1 Hz, 1 H)

Compound 36: NaBH3CN 10.2 mg (0.162 mmol, 2 equiv.) and AcOH 4.7μL were
added to a solution of 33 mg of compound 31 (0.081 mmol) and 7.5 mg (0.33mmol, 1
equiv.) compound 7 in 1 mL MeOH. The reaction mixture was stirred at room
temperature for 16 h. After diluting the reaction with ethyl acetate, the organic layer was
washed with NaHCO3, dried over MgSO4, and then evaporated under reduced pressure.
The residue was purified by silica gel chromatography (DCM/methanol 95:5). Compound
36 (17 mg) was obtained in 34% yield. 1H NMR (500 MHz, CDCl3) δ ppm 1.16 - 1.43
(m, 8 H) 1.66 (d, J=11 Hz, 3 H) 2.11 (s, 2 H) 2.36 (t, J=7 Hz, 3 H) 3.16 (br. s., 3 H) 3.65
(dd, J=13, 5 Hz, 3 H) 4.89 - 5.34 (m, 2 H) 6.23 (br. s., 1 H) 6.94 (br. s., 2 H) 7.43 (br. s.,
6 H) 8.45 - 8.60 (m, 2 H).

Compound 38: NaBH(OAc)3 (35 mg ,0.165 mmol, 1.5equiv.) was added to a solution of
31b (45 mg, 0.11 mmol) and 34 ( 18 mg, 0.11 mmol, 1 equiv.) in 1 mL DCM. The
reaction mixture was stirred at room temperature for 30 min. MeOH (0.1 ml) was added
and the mixture was concentrated. The residue was purified by silica gel chromatography
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(DCM/methanol 100:3). Compound 38 (10 mg) was obtained in16% yield. 1H NMR (300
MHz, CDCl3) δ ppm 1.25 (t, J=7 Hz, 3 H) 1.38 (s, 3 H) 1.64 (s, 3H) 1.95 (br. s., 2 H)
2.31 (d, J=6 Hz, 2 H) 2.85 - 3.17 (m, 6 H) 4.12 (q, J=7 Hz, 2 H) 5.11 (br. s., 1 H) 5.38
(br. s., 1 H) 5.97 - 6.17 (m, 3 H) 7.07 (br. s., 2 H) 7.94 (s, 1 H) 8.01 - 8.11 (m, 2 H) 8.33
(s, 2 H).

Compound 25: Compound 36 (17 mg) was dissolved in 2 mL methanol; 8.5 mg of 10%
Pd/C was added. The reaction mixture was placed under an atmosphere of H2 (50 Psi) at
room temperature for 4 h. The mixture was filtered, and evaporated under a reduced
pressure. The crude product was directly used for the next reaction without purification.
Compound 37 (12 mg) was obtained in 81.3% yield. A suspension of compound 37 (12
mg) in a mixture of 0.2 M methanolic HCl (1ml) and H2O (0.1 ml) was stirred at room
temperature for 16 h. After adjusting the pH 7.0, the reaction mixture of compound 40
was directly used for the next reaction without purification. To a suspension of compound
40 (15 mg), in a mixture of MeOH/H2O (10:1, 1 ml: 0.1 ml), was added 22 mg of KOH
in one portion. The mixture was stirred at room temperature for 16 h and then
concentrated under reduced pressure. The residue was purified by HPLC. The flow rate
was 3 ml/min. The mobile phase consisted of a mixture of MeCN-H2O, (started from
15:0 V/V till 15: 90 V/V)). The retention time was 1.2 min.

Compound 26: A suspension of compound 38 (8.6 mg) in a mixture of 0.5 M methanolic
HCl (1mL) and H2O (0.2 mL) was stirred at room temperature for 6 h. After adjusting the
pH to 7.0, the reaction mixture of compound 41 was directly used for the next reaction
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without purification. To a suspension of compound 41 (8.6 mg) in a mixture of MeOH:
H2O (1 ml: 0.3 ml) was added 9.6 mg of KOH. The mixture was stirred at room
temperature for 42 h and then neutralized by acetic acid. The solvent is evaporated at a
reduced pressure and the residue was purified by silica gel chromatography (DCM /
methanol 1:1). A yellow foam (5.8 mg, 72%) from 26 was obtained. 1H NMR (500 MHz,
CD3OD) δ ppm 1.79 (br. s., 3 H) 2.18 (d, J=5 Hz, 3 H) 2.59 - 2.74 (m, 2 H) 2.88 - 3.08
(m, 3 H) 4.07 (d, J=6 Hz, 1 H) 4.14 - 4.33 (m, 2 H) 4.78 (d, J=4 Hz, 1 H) 5.99 (d, J=5
Hz, 1 H) 7.29 (d, J=8 Hz, 2 H) 7.99 - 8.08 (m, 2 H) 8.21 (s, 1 H) 8.32 (br. s., 1 H)

5.6 Conclusions and Future Studies
DNA methylation inhibition is an emerging area. Although the first inhibitors were
discovered in the sixties, there are still a lot of demands to develop more potent and less
toxic inhibitors, opening a promising road ahead to future therapies. A series of SAHderived DNMT inhibitors was designed using a combination of mechanism-based design
(transition state inhibitor) and structure-based modifications. The inhibition activities will
be tested in vitro using human DNMT1 assays in future studies. The future perspectives
lie in developing more similar compounds and elucidating their mechanisms of action in
order to develop more effective DNMT1 inhibitors.
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